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Triple negative breast cancers (TNBC) can be classified as one of the most 
aggressive with a high rate of local recurrences and systematic metastases. 
TNBCs are insensitive to existing hormonal therapy or targeted therapies such 
as the use of monoclonal antibodies, due to the lack of estrogen receptor (ER) 
and progesterone receptor (PR) and the absence of overexpression of human 
epidermal growth factor receptor 2 (HER2) compared with other types of 
breast cancers. The absence of targeted therapies for selective delivery of 
therapeutic agents (TAs) into tumours, coupled with the multidrug resistance 
(MDR) which prevents their delivery, leads to the two consequences: the 
ineffectiveness of conventional chemotherapy on TNBC cells   and 
considerable side effects to healthy cells due to non-specificity of the 
chemotherapeutic agents. Although nanomedicine has shown superior killing 
effects on TNBC cells compared with free drugs, there is need to identify the 
possible targeting agents in order to effectively deliver the nanomedicine into 
metastatic TNBC cells. At the outset of this study, only a handful of 
publications have reported the possible targeting agents used in clinical studies 
for the treatment of TNBCs. From clinical studies, TNBC patients have been 
found to show superior response rates with the combination therapy of 
chemotherapy and the anti-EGFR monoclonal antibody, cetuximab, compared 
with chemotherapy alone. However, the conventional method of delivering 
both cetuximab and the chemotherapeutic agents as free drugs does not show 
long term efficacy and therefore leads to a high rate of recurrences. We 
postulated that novel targeted nanomedicines – by virtue of the ability of 
nanocarriers to transport drugs specifically into the TNBC cells, compared 
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with free drug molecules – could enhance the delivery of chemotherapeutic 
agents into cells, thereby improving the killing effects and reducing the rate of 
recurrence. 
In this study, we developed a targeted micellar system of cetuximab-
conjugated micelles of D-α-tocopheryl polyethylene glycol succinate (vitamin 
E TPGS) for targeted delivery of docetaxel as a model anticancer drug for the 
treatment of TNBCs. The in vitro cytotoxicity studies has shown that TNBC 
cells exhibited a greater degree of drug resistance than the ER/PR or HER2 
positive breast cancer cells after treatment with the free docetaxel drug, 
Taxotere® (Dox) which is used commercially in clinical studies. Interestingly, 
the drug resistance can be greatly attenuated by the docetaxel-loaded vitamin 
E TPGS (TPD) micellar formulation and further still by the cetuximab-
conjugated, docetaxel-loaded vitamin E TPGS micelles (TPDC) to target the 
EGFR-overexpressing TNBC cells. Then, we used the EGFR-overexpressing 
cell line, MDA-MB-231/Luc, to develop the TNBC xenograft model in female 
CB-17 Severe Combined Immunodeficiency (SCID) mice. The real time in 
vivo biodistribution and tumour targeting ability of the micelles after 
intravenous injection (i.v.) were studied by the noninvasive IVIS® imaging 
system. The anti-tumour effects of the TPGS, docetaxel loaded targeting and 
non-targeting TPGS micelles were evaluated using the TNBC xenograft 
model, and compared with Taxotere®. 
In order to elucidate the behaviours of the cancerous cells after the 
nanomedicine treatment, we performed explant cultures of the tumours pre-
treated with one of our micelle formulations, and attempted to re-examine in 
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greater detail whether our drug-micelle system was indeed efficacious through 
ex vivo investigation. The ex vivo study has demonstrated that tumours treated 
with targeting micelles exhibited enhanced cell cycle arrest and attenuated 
proliferation compared with the control and with those treated  non-targeting 
micelles. Furthermore, the ex vivo investigation revealed that both the 
targeting and non-targeting micellar formulations culminated in anti-
angiogenesis effects and inhibition of metastases. Overall, both the in vivo and 
ex vivo data increased the confidence that our micellar formulations, TPDC, 
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Chapter 1 Introduction 
1.1 Background 
Cancer is one of the leading causes of death worldwide that is typically 
characterized by uncontrolled cell growth caused by up regulation of 
oncogenes or down regulation of tumour suppressor genes and angiogenesis 
(Siegel et al. 2015). Breast cancer is generally classified based on the types of 
receptors found on their cell surface, which include hormone receptors like the 
progesterone receptor (PR), the estrogen receptor (ER), and the epidermal 
growth factor receptor 2 (HER2). Triple negative breast cancers (TNBC) lack 







170,000 patients are diagnosed annually worldwide to have TNBC (Siegel et 
al. 2015). TNBC can be classified as one of the most aggressive cancers with a 
high rate of local recurrences (< 5 years) and systematic metastases that are 
insensitive to current cancer therapies (Dent et al. 2007; Duffy et al. 2012; 
Ismail-Khan & Bui 2010). Although chemotherapy drugs such as 
anthracyclines and taxanes are treatment options currently available for 
TNBC, this strategy is not sufficiently effective to treat metastatic TNBC.  
This ineffectiveness stems from the lack of targeted therapy failure required to 
effectively deliver the drugs into tumours with minimal side effects to healthy 
cells. In addition,  multi-drug resistance (MDR) exhibited by the TNBC 
tumour further prevents the delivery of therapeutic agents (TAs) into the 
tumours (Arnedos et al. 2012; Martin et al. 2014; Rivera & Gomez 2010).  
Nanomedicine offers multipronged solutions to counter these problems from 
different angles. By tuning the surface chemistries and surface molecules, 
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nanomedicine can deliver the TAs into the targeted cells via receptor-mediated 
endocytosis (RME) (Tan et al. 2014; Kutty & Feng 2013; Kutty et al. 2014; 
Martin et al. 2014; Muthu et al. 2015). This strategy also improves the 
pharmacokinetics profile of TAs and controls the release of TAs (Tan et al. 
2014; Feng & Chien 2003; Zhang et al. 2012; Mi et al. 2012). In addition, 
nanocarriers overcome MDR by providing protection to TAs and prevent 
elimination by the P-glycoproteins (P-gp) (Kim et al. 2013; Feng & Chien 
2003). There are a few exciting examples of various nanomedicine 
applications targeting TNBC (Johnstone et al. 2013; Taurin et al. 2013; Burke 
et al. 2012). Problems with conventional chemotherapy in terms of its 
formulation, pharmacokinetics and drug resistance may be solved with the 
help of nanomedicine. However, as the tumour progresses to the later 
metastatic stages, TNBC begin to develop resistance to most chemotherapeutic 
drugs and that initiates a slippery slope towards mortality, often occurring 
within 12 months after treatments ends (Duffy et al. 2012; Dent et al. 2007). 
Further confounding the situation, the mainstream drugs such as tamoxifen 
and trastuzumab (Herceptin®), though efficacious against other non-TNBC 
(Raff et al. 2004; Wong & Chen 2012), does not work for TNBC without the 
support of targeted delivery. Hence, there is a clear need to explore effective 
targeting methods to improve the delivery of drugs to TNBC. 
Progression of cancer is often accompanied by the overexpression of special 
proteins called tumour antigens that can be used as biomarkers to differentiate 
cancerous cells from healthy ones for the development of targeting strategies. 
Several studies have reported that EGFR is overexpressed (27–57%) in basal-
like TNBC (Lehmann et al. 2011). Excessive EGFR signalling can arise from 
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receptor overexpression, autocrine signalling or mutation. Cancer cells 
usually express 20- to 50- fold higher of EGF receptors per cell compared 
to normal cells (Milenic et al. 2008; Herbst & Shin 2002). Thus EGFR 
receptor shows great promise as a target for delivery (Nielsen et al. 2004). 
In the present study, we engineered a nanocarrier to target and deliver  the 
chemotherapeutic agent, docetaxel (N-Debenzoyl-N-(tert-butoxycarbonyl)-10-
deacetyltaxol), into  TNBC cells.  D-α-tocopheryl polyethylene glycol 
succinate (Vitamin E TPGS, or simply TPGS) was used to synthesize micelles 
for encapsulation of  docetaxel. Vitamin E TPGS comprising of both lipophilic 
alkyl tails and hydrophilic polar heads result in micellar formation above its 
critical micelle concentration (CMC) of 0.02 wt%.  Furthermore, TPGS also 
provides a large surface area which can be modified for ligand conjugation for 
targeted drug delivery. TPGS micelles is one of the most developed 
nanocarriers which have been shown advantages for drug delivery, namely 
higher hydrophobic drug encapsulation efficiency, better stability, a more 
desirable controlled release rate and a higher cellular uptake efficiency 
compared with other FDA-approved biocompatible materials such as 
poly(lactic-co-glycolic acid) (PLGA) (Mu & Feng 2002; Muthu et al. 2011; 
Chandrasekharan et al. 2011).   
In this research, docetaxel is chosen as the model anticancer agent. 
Mechanistically, docetaxel binds to microtubules and leads to mitotic arrest in 
the G2/M phase of the cell cycle, thereby resulting in cell death.  Cetuximab is 
used as the targeting antibody. Cetuximab, approved in  February 2004, is the 
first human chimeric monclonal antibody that binds specifically to the 
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extracellular region of EGFRs. It prevents both ligand binding and 
dimerization with other HER family members. It was also found that 
cetuximab can induce EGFR internalization, which further facilitates the 
internalization of the micelles by cells.  
1.2 Hypothesis and objectives 
It is hypothesized that vitamin E TPGS micelles decorated with cetuximab 
targeting moieties on its surface will be able to specifically recognise and bind 
to EGFR-overexpressing TNBC cells. This therefore enhances the delivery of 
docetaxel into cells, thus improving the therapeutic efficacy and reducing side 
effects.  
The objective of this study is to investigate the effectiveness of cetuximab-
conjugated docetaxel-loaded vitamin E TPGS micelles (TPDC) for the 
targeted drug delivery to EGFR-overexpressing TNBC cells. The aim of the 
study is to develop a novel system of TPDC micelles by using one of the well-
established materials vitamin E TPGS. The focus lies on the modification of 
the surface properties with cetuximab to achieve desired surface properties, 
size, higher drug loading and enhanced cellular uptake. The efficacy of the 
targeted micellar formulation is assessed in vitro using a diverse range of 
EGFR-overexpressing TNBC cell lines. In addition this study aims to evaluate 
the biodistribution and anti-tumour efficacy of the micellar formulation in 
TNBC xenograft models. Finally, we further validate the finding ex vivo in 




Chapter 2 Literature Review 
2.1 Cancer 
Cancer is a disease characterized by sustained proliferation of malignant cells 
and the resultant generation of tumours. Malignant tumours often invade 
neighboring tissues or organs and also undergo metastasis by entering into the 
blood stream (Chow 2010). Cancer is a very common disease. An estimated 
1,658,370 cases are expected to be newly diagnosed in the United States 
(Siegel et al. 2015).  
2.1.1 Types of breast cancer 
Breast cancers are generally classified based on the type of receptors present at 
the molecular level: progesterone receptor (PR)-positive; (2) estrogen receptor 
(ER)-positive; (3) epidermal growth factor receptor 2 (HER2)-positive; triple 
positive (in which all PR, ER and HER2 are found in the breast cancer cells); 
and triple negative (in which none of the receptors are found). The 
classifications of tumours provide important information on the action of the 
tumours and aid the physician in the selection of the corresponding therapeutic 
regimens for the patient. For ER- or PR-positive tumours, endocrine therapy 
tumours involving selective estrogen receptor modulators (e.g. tamoxifen) or 
aromitase inhibitors (e.g. anastrozole) is clinically used to prevent recurrence 
after surgery (Wong & Chen 2012).  For HER2 over-expressing tumours 
tumours, the antibody herceptin is used to bind HER2 receptors  for inhibiting 
cell proliferation (Baselga et al. 1998; Hudis 2007; Raff et al. 2004). However, 
triple negative patients are not sensitive to existing hormone therapies or anti-
HER2 antibodies, and there is no targeted therapy developed to help prevent 
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recurrence of the tumours (Dent et al. 2007; Duffy et al. 2012; Foulkes et al. 
2010).  
2.1.2 Triple negative breast cancer (TNBC) 
Triple negative breast cancer (TNBC) is the most difficult type of cancer to 
cure due to a high rate of recurrence and distant metastases compared with 
other types of breast cancer (Dent et al. 2007). TNBC is characterized by the 
lack of expression of estrogen receptor (ER), progesterone receptor (PR) and 
human epidermal growth factor receptor-2 (HER2) (Foulkes et al. 2010).  It 
has been found that approximately 15% of breast cancer patients are 
diagnosed with TNBC and that it frequently affects younger, African-
American and Hispanic women of a lower socio-economic background (Bauer 
et al. 2007). Given the heterogeneous nature of TNBC, the identification of the 
molecular subtypes is essential for understanding the biological characteristics 
and clinical behavior and for facilitating the determination of molecular 
drivers that can be therapeutically targeted. Cluster analysis has identified six 
TNBC subtypes based on the gene expression profile, including two basal-
like, an immunomodulatory, a mesenchymal,  a mesenchymal stem-like  and a 
luminal androgen receptor  subtype (Lehmann et al. 2011). However, a 
majority (80%) of TNBC cases express markers of basal such as basal 
cytokeratin (5, 6, 14 and 17), vimentin, epidermal growth factor receptor 
(EGFR), mutated BRCA1/2 and deleted p53, thereby leading to its 
classification as the basal-like phenotype (Lehmann et al. 2011; Rakha & Ellis 
2009; Rakha et al. 2007; Pal et al. 2011).  TNBC with basal-like subtypes are 
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generally more aggressive tumours and are associated with poorer outcomes 
compared with other subtypes of breast cancer (Bauer et al. 2007). 
Patients with TNBC have been observed to have a higher risk of recurrence in 
the first five years of the treatment compared with those with non-TNBC 
(Dent et al. 2007). These patients were significantly more likely to have 
visceral metastases, which might contribute to their poorer prognosis. 
However, even in very early breast cancers, the risk of recurrence is higher in 
the tumours TNBC compared to HER2 positive tumours when adjusted for 
prognostic factors such as age, tumour size, and adjuvant treatment (Kaplan et 
al. 2009). The triple negative phenotype is associated with lower median 
durations of survival following recurrence than other subtypes. In an analysis 
of 3,726 early stage breast cancer patients, the median survival in the basal-
like subgroup following distant recurrence was 0.5 years, compared with 2.2 
years for the luminal A subgroup, and 0.7 years for the HER2 amplified 
cohorts (Kennecke et al. 2010). 
2.2 Limitations in current cancer therapies for TNBC   
Surgical removal of tumours is usually the first consideration in cancer 
treatment. Unfortunately, surgery has a few drawbacks. Firstly, surgery can 
only be performed when the tumours are sufficiently large and, because of its 
invasive nature, carries risks of wound infection.  Secondly, for patients with 
medical history such as hemophilia, surgery may not be feasible. Thirdly, 
though surgery can successfully remove the tumours, it may trigger metastasis 
(Weiss & DeVita 1979).  Lastly, surgery is usually coupled with radiotherapy 
(in which ionizing radiation is used to damage the DNA of cells) and 
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chemotherapy (in which highly toxic anticancer drugs are used to inhibit 
tumour growth). Both these modalities attack rapidly dividing cancer cells, but 
they also affect dividing cells of normal tissues and lead to undesirable side 
effect. 
2.2.1 Surgery 
Surgical excision remains the best method for the localized removal of the 
TNBC tumours, similar to other forms of breast cancers. Breast conservation 
treatment (BCT), followed by radiation treatment (RT), is one conventional 
treatment for patients with TNBC. The risks of local and regional recurrences 
have been reviewed (Freedman et al. 2009; Haffty et al. 2006; Nguyen et al. 
2008; Yagata et al. 2011). Haffty et al. and Freedmann et al reported that no 
significant difference was observed between TNBC and non-TNBC patients in 
terms of breast recurrence free survival at five years after treatment with 
breast-conserving surgery and radiation (Freedman et al. 2009; Haffty et al. 
2006). In contrast, Nguyen et al. reported a higher local recurrence rate at five 
years was observed for the basal-like subtype compared  with other subtypes 
(Yagata et al. 2011). 
2.2.2 Radiotherapy 
Radiotherapy is an important type of cancer treatment today. Indeed, about 
half of all cancer patients undergo radiation usually after surgery and 
combined with chemotherapy. Radiotherapy involves the use for ionizing 
radiation to destroy cancer cells by damaging the DNA within these cells. In 
TNBC treatment, radiotherapy plays an instrumental role in preventing local 
recurrence of tumours after lumpectomy or mastectomy. Kyndi et al. reported 
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that radiotherapy decreased local recurrence after mastectomy in TNBC. 
However, no improvement in overall survival was observed for radiation in 
TNBC (Kyndi et al. 2008). Voduc et al. reported that radiotherapy reduced 
regional recurrence significantly but decreased local recurrence after 
mastectomy only marginally (Voduc et al. 2010). 
2.2.3  Chemotherapy  
Chemotherapy is the only systemic therapy currently available for TNBC 
patients.  There are, however, no standard chemotherapy regimens for TNBC. 
Commonly used chemotherapy regimens in breast cancer include 





 tumours were more sensitive to neoadjuvant anthracyline-based 
therapies (Carey et al. 2007; Isakoff 2010). These findings were further 
supported by Liedtke et al. was pathologic complete response (pCR) rate for 
TNBC patients doubled compared to non-TNBC after neoadjuvant 
chemotherapy. These studies showed that TNBC patients who achieved a pCR 
would have an excellent long term outcome, compared with those who not 
have higher risk of recurrence and death than patients with non-TNBC 
(Liedtke et al. 2008; Isakoff 2010). 
However, the role of certain chemotherapeutic agents in the treatment of 
TNBC remains unclear and more studies are required to ensure that the most 
effective therapy is delivered with minimal toxicity. The benefits of taxanes in 
adjuvant therapy of TNBC have been realized over the past few years. 
Henderson et al. reported that the addition of paclitaxel resulted in a 17% 
reduction in the risk of recurrence with an improvement in five year disease-
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free and overall survival rate (Henderson et al. 2003; Isakoff 2010).  In the 
context of metastases, several clinical trials have shown that taxanes have less 
benefit to TNBC over other subtypes. Harris et al. reported that TNBC patient 
has a poor overall survival compare with other subtypes (Harris et al. 2003).  
2.2.4 Lack of targeted therapy for TNBC 
Targeted therapy refers to the ability to deliver drugs or drug loaded carrier 
into the tumour site by specific interaction with receptor of the cancer cells at 
the molecular level. TNBC is not amenable to existing targeted therapy such 
as hormonal therapy or tailored treatment with monoclonal antibodies due to 
the lack of ER and PR and the absence of overexpression of HER2.  
Consequently, metastatic TNBC is an aggressive disease where the patients 
have a much shorter median time from relapse to death (Dent et al. 2007). 
Therefore, identification of specific targeted and more active therapies for 
TNBC patients remains an important clinical challenge. Various gene 
expression studies have been conducted in order to identified potential 
molecular targets that may serve as targets for specific therapeutic such as 
epidermal growth factor receptor (EGFR), proto-oncogene tyrosine-protein 
kinase Src (SRC), MET proto-oncogene, receptor tyrosine kinase (MET) and 
poly ADP ribose polymerase 1/2 (PARP1/2) (Lehmann et al. 2011; Duffy et 
al. 2012). 
2.3 Factors influencing TNBC insensitivity to conventional 
chemotherapy  
There are four majors factor that heavily determine the effectiveness of a 
chemotherapeutic effort. Chief amongst them is dosage form. The 
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hydrophobicity of certain anticancer drugs necessitates the use of solubilizers 
or adjuvants such as Cremophor EL (for paclitaxel) and Tween-80 (for 
docetaxel) to increase the solubility of the drugs.   These excipients, however,   
may cause life-threatening side effects (Fjällskog et al. 1993; Rowinsky et al. 
1992; Webster et al. 1993). Another factor is the drug pharmacokinetics. The 
administration of a proper drug dosage in accordance to designated schedules 
is important for successful chemotherapy.  The goal for chemotherapy is to 
deliver the drugs of high efficacy at the right time to the desired location with 
a concentration high enough over a sufficiently long period. However, it is 
difficult to meet those requirements using existing chemotherapy in order to 
achieve the effective delivery of drugs. In addition to that chemotherapeutic 
strategy has to iron out the systemic drug toxicity problem. Free anticancer 
drug molecules are toxic to healthy cells, especially hepatic and renal cells 
which have an important role in drug metabolism and excretion. It would be 
ideal if the chemotherapeutic drugs could exert their actions only on the 
cancerous cells (Feng & Chien 2003). Finally, cancerous cells tend to develop 
drug resistance such as MDR which leads to the failure of chemotherapy. 
There are three major categories of drug resistance: pharmacokinetic 
resistance due to the low concentration of the drug in the tumours; kinetic 
resistance due to the presence of only a small fraction of cells in a susceptible 
state; and genetic resistance due to the biochemical resistance of the tumour 
cells against the drug (Feng & Chien 2003).  Cancerous cells may also 
overexpress P-gp, which efflux drug molecules out of cells resulting in a 
reduction of the drug concentration in the cancer cells. 
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2.4 Nanomedicine: key advantages over conventional 
chemotherapy   
Nanomedicine offers several advantages over conventional treatment for 
cancers. Firstly, desirable features such as the size and surface charge of the 
nanoparticles with the desired size (for example 100–200 nm in diameter) and 
surface modification (e.g. by polyethylene glycol (PEG) or TPGS) enable 
them to escape from the reticuloendothelial system (RES); this, in turn, could 
contribute to a sustained and controlled drug release of a sufficiently long half-
life in the blood system (Feng et al. 2007). Secondly, nanomedicine allows the 
encapsulated drug molecules to accumulate in tumours via the enhanced 
permeability and retention effect (EPR), i.e. the greater vascular permeability 
of tumours for macromolecules and the impaired clearance of such 
macromolecules in the tumour interstitium (Maeda et al. 2000). Such 
selectivity could help minimize systematic toxicities (Feng et al. 2007). 
Thirdly, ligand-conjugated nanomedicines could realize targeted delivery of 
the therapeutic agent and thus enhance internalization of nanoparticles into the 
tumour via endocytosis, which avoid recognition by the P-gp (Sarin 2010). 
Finally, nanomedicine could realize co-delivery of two or more therapeutic 
agents for combined therapy to promote their synergistic effects, which can 
further improve the treatment efficacy (Tan et al. 2014). 
2.5 Nanomedicine may improve the sensitivity of TNBC   
There have been successful examples of nanomedicine treatments for TNBC 
by using various nanocarriers, such as micelles, liposomes, prodrugs and 
biodegradable polymeric nanoparticles, to deliver therapeutic agents, which 
have been proved to have significant advantages over free drugs. For instance, 
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Taurin et al.2012 synthesized a micellar system by using styrene-co-maleic 
acid (SMA) to deliver hydrophobiccurcumin (3,5-bis(3,4,5-
trimethoxybenzylidene)1-methypiperidine-4-one,RL71) for TNBC treatment.  
It was found that the micellar formulation elicited a higher cytotoxicity than 
the free drug, which may be due to its higher cellular uptake via endocytosis 
and the slow drug release profile. The finding was further supported by in vivo 
findings that the longer circulation of micelles in blood system enhanced the 
uptake into tumours and led to higher cytotoxicity  than the free drug (Taurin 
et al. 2012). In addition, Johnstone et al.2013 developed polymeric 
nanoparticles (NP) of poly(D,L-lactic-co-glycolic acid)-block-poly(ethylene 
glycol) (PLGA-PEG), which were stabilized with poly(vinyl alcohol) (PVA), 
to encapsulate the hydrophilic platinum(IV) prodrug, mitaplatin via the 
water/oil/water double emulsion method.  The pharmacokinetics and 
anticancer effects were demonstrated in a xenograft model of TNBC, in which 
MDA-MB-468 TNBC cells were grown in nude mice and subsequently treated 
with 1 mg/kg of free mitaplatin or the PLGA-PEG NP formulation (M-NP). 
The results showed that a lower dosage was required for treatment with M-NP 
to achieve the same degree of tumour inhibition with the free drug (Johnstone 
et al. 2013). Besides chemotherapy, TNBC exhibits a high sensitivity to 
nanoparticle-based photothermal therapy. Burke et al.2012 demonstrated that 
TNBC cells are resistant to conventional hyperthermia therapy, which, 
however, can be enhanced by nanoparticle-based photothermal therapies 
(Burke et al. 2012).  
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2.6 Nanomedicine in TNBC treatment: the knowledge gap 
Even though nanoparticle-based therapy has shown significant killing effects 
on the TNBC, there is need to identify the possible targeting agents in order to 
effectively deliver the nanomedicine into metastatic TNBC cells. At the outset 
of this study, only a handful of publications have been reported on the possible 
targeting agents used in clinical studies for TNBC treatment. From clinical 
studies, TNBC patients have been found to show superior response rates with 
the combination therapy of chemotherapy and the anti-EGFR monoclonal 
antibody, cetuximab, compared with chemotherapy alone (49% vs. 30%). 
However there is no significant difference between these two groups in terms 
of progression-free survival. This study leads to the postulation that the co-
delivery of chemotherapeutic agents and anti-EGFR antibodies using 
nanocarriers might improve the overall treatment for TNBC.  
2.7 Epidermal growth factor receptor (EGFR) as a potential 
therapeutic target for TNBC  
The lack of a targeted therapy has led to the search for druggable targets in 
TNBC. Receptor and non-receptor tyrosine kinases represent rational targets 
for cancer as they are frequently dysregulated in cancer, e.g. HER2 in breast 
cancer. A number of tyrosine kinases have been shown to be of particular 
importance in basal-like/triple-negative breast cancer, including EGFR, 
mitogen-activated  protein  kinase  (MAPK), protein kinase B (Akt), Src, 
tyrosine-protein kinase kit (c-kit), focal adhesion kinase (FAK), MET and 
PARP 1/2 (Duffy et al. 2012; Gelmon et al. 2012). Several studies have 
reported that EGFR is overexpressed (27%-57%) in basal-like TNBC. 
Excessive EGFR signaling can arise from receptor overexpression, autocrine 
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signaling, or mutation. Normal cells usually express 4×10
4
  to  1×10
5
   EGFRs 
per cell, but tumour cells can express as many as 2×10
6
 (Herbst & Shin 2002; 
Milenic et al. 2008). Thus EGFR is a great candidate for targeted therapy 
(Nielsen et al. 2004). 
2.7.1 Molecular mechanism of EGFR activation and response 
EGFR is one of four family type transmembrane growth factor receptor 
proteins known as erbB-1 or HER1. All four members share similarities in 
structure that is 170kDa glycoprotein that consists of ligand-binding 
extracellular domain, a transmembrane region, and an intracellular tyrosine 
kinase domain (Cohen et al. 1982). The EGFR signalling pathway regulates 
growth, survival, proliferation, and differentiation in mammalian cells (Figure 
2.1) (Oda et al. 2005). EGFR can be activated by a number of different 
ligands, such as the epidermal growth factor (EGF), transforming growth 
factor alpha (TGF-α), heparin-binding EGF, amphiregulin, betacellulin, 
epiregulin and neuregulin G2b (Harris et al. 2003). The binding of ligands 
drives receptor dimerization, and the various receptors in the EGFR family are 
capable of both homo- and hererodimerization with each other. The receptor 
dimerization event allows for kinase activation and trans-phosphorylation of 
residues in the intracellular domain. It has also been observed that activated 
EGFR may undergo nuclear translocation and subsequently regulate gene 
expression, although the contribution of this pathway compared to more 
traditional signal transduction is unclear (Lo & Hung 2006; Wells & Marti 
2002). The activation of EGFR thus leads to multiple cell responses, including 




Figure 2.1 The EGFR signalling network. Epidermal growth factor receptor 
signalling network: (a) EGFR family ligands are shown with their binding 
specificities. For simplicity, arrows are only drawn for EGF and neuregulin 4 
(NRG4), although other ligand specificities are shown in parentheses. (b) 
Signaling to the adaptor protein/kinase layer is only shown for two receptor 
dimers. (c) Possible cellular outcomes based on EGFR signaling (Yarden & 
Sliwkowski, 2001).  
2.7.2 Overexpression of EGFR in TNBC 
The expression of EGFR in cancer leads to high progression, poor survival, 
and poor response to therapy (Brabender et al. 2001), as well as the 
development of resistance to therapeutic agents. A number of studies have 
reported that EGFR is over-expressed in TNBC. Livasy et al. assessed 56 
breast tumours by immunohistochemistry and found that EGFR was detected 
in 72.2 % (13/18) of the basal-like tumours. All of the basal-like tumours were 
negative for ER and HER2 expression (Livasy et al. 2006). Kreike et al. 
performed immunohistochemistry (CK5/6, p53, EGFR, c-kit) and generated 
gene expression profiles on 97 patients with triple negative tumours. The 
authors concluded that triple-negative tumours were synonymous with basal-
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like tumours. However, there were different subgroups within basal-like breast 
cancer, and no strong overall prognostic gene expression profile, including 
EGFR, was identified. Therefore EGFR-directed therapy may be appropriate 
in some basal-like breast tumours but not necessarily all (Kreike et al. 2007). 
Rakha et al. examined a series of 1944 invasive breast carcinomas using tissue 
microarrays. Immunohistochemical analysis of markers including ER, PR, 
HER2, androgen receptor, EGFR, P-cadherin, E-cadherin, CK5/6, CK14, and 
p53, was performed. EGFR was detected in 16.5 % (286/1726) of the tumours. 
Of the triple negative tumours, 32.6 % (92/282) expressed EGFR, compared 
with 13.4 % (194/1444) of non-triple-negative tumours (p < 0.0001). Of note, 
in this study, triple-negative tumours were associated with an increased size, 
risk of recurrence and metastasis, worse overall survival and disease-free 
survival. The frequency of EGFR expression in TNBC renders it an attractive 
target for therapeutic interventions (Rakha et al. 2007). 
EGFR effector proteins include the GTPase Ras family of proteins. Oncogenic 
mutations have been described in the GTPase KRas (KRAS) gene, which 
results in constitutive activation of KRAS signaling pathway that dysregulated 
proliferation, and decreased apoptosis. The functional differences between the 
normal and oncogenic alleles have been related to point mutations (Malumbres 
& Barbacid 2003). Somatic KRAS mutations are described in various cancers, 
including pancreatic (60 %), colon (32 %), lung (17 %), and less frequently in 
leukemia and breast cancer (5 %) The efficacy of anti-EGFR inhibitors 
depends on the wild type KRAS as the mutant KRAS transmits proliferative 
and anti-apoptotic signals independent of EGFR phosphorylation (Malumbres 
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& Barbacid 2003). Consequently, KRAS mutation is routinely assessed prior 
to administration of EGFR inhibitors such as cetuximab in colorectal cancer 
(Karapetis et al. 2008). Sanchez-Munoz et al. examined 35 triple negative 
breast cancer tumours for KRAS mutations including 27 tumours which were 
characterised as basal-like (77.1 %) by real-time PCR (Sánchez-Muñoz et al. 
2010). Interestingly, no KRAS mutation was found in any of the analyzed 
tumours. In the context of overexpression of EGFR in TNBC, the low rate of 
KRAS mutation suggests a possible therapeutic role for EGFR inhibitors. 
2.8 Micelles based drug carriers for chemotherapeutic drugs 
Micelles formed from amphiphilic di- or tri-block copolymers have gained 
popular attention in nanomedicine research for their various desirable features.  
Such building blocks of copolymers are physiological-friendly and can be 
chosen to construct micelles with increased half-life and controlled drug 
release in the body.  In addition, the size of the micelles often ranges from 10–
100 nm, which is the favorable range for passive targeting through EPR effect 
of the leaky vascular and lymphatic system of tumours (Hao et al. 2005). The 
ability of the micelles to form a hydrophobic core in an aqueous environment 
can be exploited to encapsulate hydrophobic drugs (Lasic 1992).  
Another advantage of polymeric micelles is the narrow size distribution. This 
is because the self-assembled core-shell structure of the micelles mainly relies 
on the thermodynamic equilibrium achievable under the particular reaction 
condition during fabrication. As a result, micellization are sensitive to the 
CMC of the polymeric molecules constituting the micelles (Lawrence 1994; 
Letchford & Burt 2007). This is perhaps the major concern when selecting the 
19 
 
materials to develop micelles for drug delivery. If the concentration drops 
below the CMC, the dissociation of the micelles into free chains due to 
thermodynamic instability will occur, posing potential physiological risks in 
intravenous administration of a given drug. The sudden dilution of micelles by 
the blood and physiological fluids could potentially cause immediate release 
of the encapsulated drug, which could result in severe toxicity (Lawrence 
1994). 
2.9 Factors that affect the stability of self-assembled polymeric 
micelles system for drug delivery 
Self-assembled   polymeric micelles act as a vehicle to safely deliver the 
hydrophobic therapeutic agents with an increase in solubility. Although 
micelles are known as one of the effective drug delivery systems due to their 
unique properties such as their small  size (~10-100 nm) (Blanco, Shen, & 
Ferrari, 2015), ability to escape from the mononuclear phagocyte system, and 
role in improving the pharmacokinetic of drugs, the poor stability of micelles 
remains a significant challenge (Owen, Chan, & Shoichet, 2012). Several 
factors affect the stability of micelles in terms of thermodynamic and kinetic 
stability.  
One of the fundamental parameters used to determine the thermodynamic 
stability of micelles is the critical micelle concentration (CMC), a lower value 
of which indicates greater thermodynamic stability (Zana, 1996). The CMC 
value depends on the length of hydrophobic  segment: an increase in 
hydrophobicity of the copolymer will  correspond to an increase in the 
cohesion of the hydrophobic core, resulting in a lower CMC (Gaucher et al., 
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2005).  Another factor governing the thermodynamic stability of micelles is 
the drug-core interaction. The hydrophobicity of a given drug encapsulated in 
the micellar core will further augment the hydrophobicity of the polymer and 
thus lower the CMC (Lee, Cho, & Cho, 2004). A third factor is the interaction 
between the polymer chains in the corona with the aqueous environment. For 
example, an increase in the polyethyelene glycol (PEG) chain length and 
surface density on the surface of micelles will confer further protection to the 
hydrophobic core  against exposure to aqueous environment and prevent  
micellar destabilisation (Kutty, Tay, Lim, Feng, & Leong, 2015). Finally, the 
microenvironment plays a key role in micellar formation and stability.  Small 
changes of the milieu in term of temperature, solvent and preparation 
techniques  may dramatically affect the CMC and the size of micelles  thus 
formed (Yamamoto, Yasugi, Harada, & Nagasaki, 2002). Therefore it is 
important to choose proper preparation techniques and solvent in order to get 
smaller micelles with a uniform size distribution. For example, the micelles 
formed from the co-solvent evaporation technique have been found to possess 
smaller size (~30 nm) compared to those from dialysis techniques which 
yielded much bigger and non-uniform micelles (~110 nm)." 
Kinetic stability reflects the stability of micelles in an aqueous solution over 
time. It is important to characterise the kinetic stability to ensure that the 
loaded drug is not released prematurely. Kinetic stability is dependent on 
several parameters: CMC, the ratio of the hydrophilic-hydrophobic segments 
of the polymers and the loaded drugs. As regards CMC, the kinetic stability 
increases when the hydrophobic length in block copolymers  increases 
(Domeselaar, Kwon, & Andrew, 2003). The molecular weight ratio between 
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hydrophilic-hydrophobic segments allows it to resist destabilisation by the 
environment. 
2.10 Paclitaxel and docetaxel, current clinically used anticancer 
drug 
Taxanes have played an important role in the treatment of various diseases 
over the past two decades. They are hydrophobic antineoplastic agents that 
bind to microtubules leading to mitotic arrest in the G2/M phase of the cell 
cycle, and eventually results in the cell dead (DeVita & Chu 2008).The most 
common taxanes are paclitaxel and docetaxel, both approved for clinical use 
by the Food and Drug Administration (FDA) for the treatment of cancers. 
Taxanes are originally isolated from natural source of plants of genus Taxus. 
While it is not economically feasible to synthesize paclitaxel due to the limited 
availability of yew trees, the use of semi-synthetic analogues is one of the 
possible solutions. Docetaxel is a one such new generation semi-synthetic 
analogue that can serve as an alternative to paclitaxel (Figure 2.2).  
 
Figure 2.2 Chemical structure of Docetaxel. 
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2.11 Cetuximab as a targeting agent for EGFR 
Cetuximab (Erbitux, Merck Serono,UK)  is the first  human chimeric 
monclonal antibody (approved in February 2004) that  binds specifically to the 
extracellular region of EGFR.  It prevents both ligand binding and proper 
exposure of the EGFR dimerization domain, preventing dimerization with 
other HER family members (Figure 2.3). It was also found that cetuximab 
can induce EGFR internalization (Sunada et al. 1986), which may reduce the 
number of receptors available for ligand binding. The bivalency of the 
cetuximab molecule was shown to be important for its ability to internalize 
and downregulate EGFR and inhibit subsequent growth (Fan et al. 1994). In 
addition, cetuximab has been shown to exhibit  anti-angiogenic  properties,  
leading  to  even  more  effective  treatment  of  tumour xenografts  in  vivo   
(Petit et al. 1997).  Cetuximab may also induce  antibody-dependent  cellular  
toxicity (ADCC) in vivo (Zhang et al. 2007), and  its various mechanisms of 
action are further discussed in (Baselga 2001). 
 




In clinical studies, triple negative patients have shown a superior response rate 
with the combination therapy of chemotherapy and the anti-EGFR monoclonal 
antibody, cetuximab, compared with chemotherapy alone (49% vs. 30%). 
However there is no significant difference between these two groups in term 
of progression-free survival. In a Phase II study involving TNBC, the use of 
cetuximab combined with carboplatin yielded a response rate of 17%, 
compared with only 6% with cetuximab alone. In another further Phase II 
study, the combination of cetuximab and cisplatin increased both overall 
response rate and progression-free survival, compared with cisplatin alone 
(Duffy et al. 2012).  
2.12 Vitamin E TPGS based nanocarrier and its advantages 
D-α-tocopheryl polyethylene glycol 1000 succinate (Vitamin E TPGS or 
simply TPGS) is a water-soluble molecule with a molecular weight of 
approximately 1513, which is synthesized from esterification between D-α-
tocopheryl acid succinate and polyethylene glycol (PEG) 1000 (Figure 2.4 
and Figure 2.5). TPGS is a white or slightly yellowish, waxy solid with a 
melting point of 37–41oC (Gan & Feng 2010; Zhang et al. 2012). The 
amphiphilic nature of TPGS results in a hydrophile–lipophile balance (HLB) 
of 13, rendering it an effective surfactant. HLB is a parameter used to estimate 
the emulsification stability of a non-ionic surfactant, with a higher value  
signifying a higher degree of hydrophilicity in the molecular structure and 
enhanced emulsifier function (Griffin, 1954).  
Moreover, TPGS possesses a large surface area which is important for surface 
modification for conjugation of ligands. In addition, TPGS can form micelles 
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upon dissolving in water at a concentration above its CMC value of 0.02 wt%, 
and other liquid-like crystalline phases when concentration keeps increasing 
but well below 20 wt% (Ismailos et al. 1994).  TPGS is also widely used as an 
emulsifier, solubilizer, absorption enhancer and stabilizer. As regards 
pharmaceutical application, TPGS has been intensively applied in the 
development of various drug delivery systems. The presence of PEG and 
vitamin E has been found to improve the half-life of drugs in plasma by 
preventing opsonisation and enhancing cellular uptake of the drug molecules. 
TPGS also possesses advantages such as inhibiting membrane transporters, 
specifically P-gp; overcoming MDR; and augmenting intestinal permeability 
and bioavailability of certain drugs. TPGS has also found utility in 
nanomedicine, given its ability to enhance permeability and solubility of 
hydrophobic drugs and to afford controlled and sustained delivery of drugs, as 
exemplified by TPGS-based prodrugs (Mi et al. 2012), micelles 
(Chandrasekharan et al. 2011; Muthu et al. 2015; Liu et al. 2010), liposomes 
(Muthu et al. 2012), and TPGS-based copolymers nanoparticles (Zhang et al. 
2012). 
 





Figure 2.5 Molecular structure and various segments of TPGS  
2.13 Problem statement  
The poorer prognosis for triple-negative breast cancer (TNBC) relative to 
other breast cancers is characterized by its higher incidence of recurrence and 
more aggressive clinical course. TNBC is less amenable to treatment because 
of its insensitivity towards existing medical interventions and of the lack of 
targeted therapy for effective delivery of chemotherapeutic agents into 
metastasised TNBC cells. We postulated that novel targeted nanomedicines – 
by virtue of the ability of nanocarriers to transport drug molecules specifically 
into the TNBC cells, compared with free drug molecules – could enhance the 
delivery of chemotherapeutic agents into cells, thereby improving the killing 
effects and reducing the rate of recurrence.  
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Chapter 3  In vitro proofs of concept that cetuximab- 
conjugated vitamin E TPGS micelles increases efficacy of 
delivered docetaxel against triple negative breast cancer  
3.1 Introduction 
We developed a system of cetuximab-conjugated micelles of vitamin E TPGS 
for the targeted delivery of docetaxel as a model anticancer drug for the 
treatment of triple negative breast cancer, which are less amenable to existing 
pharmacological interventions due to the lack of expression of  PR, ER 
receptor and HER2. The micelles have been shown to possess a favourable 
particle size, drug loading, drug encapsulation efficiency and drug release 
profile. Their surface morphology, surface charge and surface chemistry have 
also been characterized. For the in vitro assessment of the cellular uptake of 
the coumarin-6 loaded TPGS micelles and the cytotoxicity of docetaxel 
formulated in the micelles, a diverse array of cells were employed, including 
HER2-overexpressing breast cancer cells (SK-BR-3), ER- and PR-
overexpressing breast cancer cells (MCF-7), and TNBC cells of high, 
moderate and low EGFR expression (MDA-MB-468, MDA-MB-231 and 
HCC38). 
3.2 Materials & Methods 
3.2.1 Materials 
Erbitux® (cetuximab 5 mg/mL, 20 mL) was purchased from Merck Serono, 
UK. Docetaxel (anhydrous, 99.56% purity) was obtained from Shanghai Jinhe 
Bio-Technology Co. Ltd, China. Taxotere®, the clinical formulation of 
docetaxel, was supplied by Aventis Pharmaceuticals (NJ, USA). Vitamin E 
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TPGS (D-α-tocopheryl polyethylene glycol 1000 succinate, 
C33O5H54(CH2CH2O)23) was obtained from Eastman Chemical Company, 
USA. 1,10-carbonyldiimidazole (CDI), ethylenediamine, dioxane, chloroform, 
dimethyl sulfoxide (DMSO), acetonitrile, dichloromethane (DCM),  coumarin 
6, phosphate buffered saline (PBS, pH 7.4), N-(3-dimethylaminopropyl)-N-
ethylcarbodiimide hydrochloride (EDC), N-hydroxysuccinimide (NHS), 
Bradford reagent (for 1 - 1400 µg/mL protein),  triethylamine (TEA), 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, trypsin-
ethylenediaminetetraacetic acid (EDTA), sodium hydroxide (NaOH) and 
propidium iodide (PI) were all purchased from Sigma-Aldrich (St. Louise, 
MO, USA). Ethanol was obtained from VWR Singapore Pte Ltd. Tween-80 
was obtained from ICN Biomedicals, Inc. (OH, USA). Triton X-100 was 
obtained from USB Corporation (OH, USA). Alexa Fluor® 488 mouse anti-
human IgG1, fetal bovine serum (FBS) and penicillin-streptomycin solution 
were provided by Invitrogen. Dulbecco’s Modified Eagle’s Medium (DMEM) 
and Roswell Park Memorial Institute (RPMI) 1640 medium was purchased 
from Thermo Scientific Hyclone (South Logan, USA). Leibovitz’s L-15 
medium was purchased from Gibco Life Technologies (AG, Switzerland). All 
solvents used in this study were HPLC grade. All chemicals were used without 
further purification. Ultrapure (UP) water was prepared by a Milli-Q Plus 
System (Millipore Corporation, MA, USA). Amicon ultra-15 centrifugal filter 
units (molecular weight cut-off (MWCO): 100K) were purchased from Merck 
Millipore (Billerica, MA).  TNBC cells (HCC38, MDA-MB-231, MDA-MB-
468), positive breast cancer cells SK-BR-3, and MCF-7, and fibroblast cells 
(NIH 3T3) were obtained from American Type Culture Collection (ATCC). 
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3.2.2 Synthesis of TPGS-NH2 
For the synthesis of amine terminated TPGS (TPGS-NH2), TPGS was first 
activated by carbonyldiimidazole (CDI) to form an imidazole carbamate 
intermediate (TPGS-CDI) according to previous methods (Zhao et al. 2013). 
TPGS-NH2 was then synthesized by reacting TPGS-CDI with 
ethylenediamine. Briefly, TPGS-CDI and ethylenediamine with a 
stoichiometric molar ratio of 1:5 were dissolved in DMSO and stirred under 
nitrogen at room temperature for 24 h.  The reaction mixture was then 
dialyzed (MWCO 1000) against DMSO for 48 h and then against UP water for 
another 48 h. TPGS-NH2 powder was obtained after freeze drying. 
3.2.3 Preparation of docetaxel- or coumarin-6 loaded TPGS micelles 
Docetaxel-loaded micelles were prepared according to the solvent casting 
method as mentioned in our earlier publications (Muthu et al. 2011). Briefly, 
docetaxel (2 mg) or coumarin 6 (1 mg) was added into a chloroform solution 
of TPGS (50 mg). The organic solvent was removed by rotary vacuum 
evaporation (water bath temperature set to 40°C). The resultant thin film was 
further dried  in vacuo overnight and hydrated in 1×PBS buffer. The mixture 
was incubated at 37°C under constant agitation and then sonicated for a few 
minutes. The resultant mixture was filtered through a 0.2 µm polyethersulfone 
syringe to remove excess docetaxel or coumarin 6. The targeting micelles 
were prepared similarly, except that 20 wt% of TPGS was replaced by TPGS-
NH2. (Hereafter, we abbreviate the formulations as follows: docetaxel-loaded 
vitamin E TPGS micelles (TPD), cetuximab-conjugated docetaxel-loaded 
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vitamin E TPGS (TPDC), and coumarin 6-loaded vitamin E TPGS micelles 
(TPM), cetuximab-conjugated coumarin 6-loaded vitamin E TPGS (TPMC).) 
3.2.4 Cetuximab conjugation to the docetaxel-loaded micelles 
The cetuximab was conjugated to micelles by a reported carbodiimide 
chemistry method (Liu et al. 2010; Shamsipour et al. 2009) with a slight 
modification. In brief, 8 mg of NHS and 40 mg of EDC were added to 5 mL of 
3 mg/mL micelles. The pH of the reaction mixture was adjusted to 8.4 with 
sodium borate buffer (pH 8.4) and followed by the addition of cetuximab of a 
concentration range of 0.01–0.20 mg/mL. After 4 h reaction under room 
temperature with gentle end-to-end mixing, the micelles were collected by 
centrifugation using centrifugal filter units with MWCO 100 kDa (Amicon 
ultra-15mL). The supernatant was collected for measurement of the antibody 
concentration using the Bradford assay. 
3.2.5 Particle size and surface charge of micelles 
The particle size and size distribution of the micellar samples were measured 
by dynamic light scattering (DLS, 90 Plus, Brookhaven Instruments Co., TX, 
USA) in an aqueous medium. The surface charge was determined with a 
Zetasizer (Malvern Nano ZS, Malvern Instruments Ltd., Worcestershire, UK) 
at room temperature. The micelles were diluted with UP water to a count rate 
of 300–500 kilo counts per second (kcps) and sonicated for 5 min before 
measurement to ensure even dispersion. 
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3.2.6 Surface morphology of the micelles 
The shape and surface morphology of the micelles was visualized with a field 
emission transmission electron microscope (FETEM, JEM-2200FS, JEOL, 
Japan). Samples were prepared by placing a drop of the micellar solution on a 
copper grid and then dried in vacuo. 
3.2.7 Surface chemistry of the micelles 
Surface chemistry of the micelles was analyzed by X-ray photoelectron 
spectroscopy (XPS, Kratos Ultra DLD, Shimadzu, Japan) under fixed 
transmission mode with a pass energy of 80 mV and a binding energy range of 
0–1100 eV. The micelle sample was prepared by dropping the solution onto 
glass slides and drying in vacuo.   
3.2.8 Docetaxel loading into micelles 
The amount of docetaxel encapsulated in the micelles was measured by high 
performance liquid chromatography (HPLC, Agilent LC1100). A reversed 
phase Inertsil® ODS-3 column (150 × 4.6 mm, particle size 5 mm, GL 
Science Inc., Tokyo, Japan) was used. 1 mL micelles were freeze-dried and 
dissolved in 1 mL DCM. After evaporating DCM, 1 mL mobile phase 
consisting of acetonitrile and water solution (50:50 v/v) was added to dissolve 
the drug. After centrifugation at 13,000 rpm for 5 min, a supernatant of the 
suspension was collected and the solution was then filtered   with a 0.45 mm 
PVDF syringe filter for HPLC analysis. The column effluent was detected at 
230 nm with a UV/VIS detector, with the flow rate set to be 1.0 mL/min. The 








3.2.9 Determination of cetuximab surface density on micelles 
The Bradford assay as per standard protocol was employed for quantifying the 
concentration of cetuximab in the supernatant. The amount of the ligand 
conjugated to the micellar surface was obtained via reduction of the amount in 
the supernatant from the initial amount. Briefly, 50 µL of cetuximab solution 
was mixed with 1.5 mL Bradford reagent and incubated for 15 min before 
measuring absorption at 590 nm using a UV-Vis spectrophotometer (UV-
1601, Shimadzu, Japan). 
3.2.10 In vitro drug release of docetaxel from micelles in buffer solution 
5 mL solutions of docetaxel-loaded vitamin E TPGS micelles (TPD) and of 
cetuximab-conjugated docetaxel-loaded vitamin E TPGS micelles (TPDC) 
were respectively placed in a dialysis bag (MWCO: 10 kDa) with 0.1%w/v 
Tween-80. The dialysis bags were incubated in 10 mL PBS (0.1 M, pH 7.4) 
containing 0.1% (v/v) Tween-80 at  37°C with gentle shaking at 90 rpm. Since 
docetaxel is insoluble in the buffer solution, 0.1% w/v tween 80 was added to 
simulate the sink condition. The incubation buffer was collected and replaced 
by a fresh incubation buffer at fixed time points. The collected buffer, 
including the released drugs, was centrifuged at 13,000 rpm for 20 min at 4
o
C. 
The supernatant was drained and the pellet re-suspended with a mobile phase 
consisting of acetonitrile and water solution (50:50 v/v). The amount of drug 
released was determined by the HPLC (Agilent LC1100, Agilent, Tokyo, 
Japan) method as described in the drug encapsulation determination. 
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3.2.11 Cell culture 
NIH 3T3, SKBR-3, MCF-7 and MDA-MB-231 were grown in DMEM 
supplemented with 10% FBS and 1% penicillin-streptomycin solution. HCC 
38 cells were grown in RPMI 1640 medium supplemented with 10% FBS and 
1% penicillin-streptomycin solution. MDA-MB-468 cells were grown in 
Leibovitz (L-15) media supplemented with 10% (v/v) FBS and 1% (v/v) 
penicillin-streptomycin solution in the absence of carbon dioxide (CO2). All 
other cell lines were grown at 37
o
C in the presence of 5% CO2. 
3.2.12 Flow cytometry analysis for EGFR expression of cell lines 
The EGFR expression of the cell lines was evaluated by standard flow- 
cytometry.  Briefly, after reaching confluence, cells were trypsinized, pelleted 
at 1,500 rpm for 5 minutes and re-suspended in phosphate-buffered saline 
(PBS; pH 7.2) containing 1% bovine serum albumin (BSA/PBS). Then 1 µg of 
cetuximab (Erbitux; Merck Serono,UK) was added and incubated for 1 h   at 
4°C. The cells were washed three times with (BSA/PBS) and pelleted at 1,500 
rpm for 5 minutes, and decanted the supernatant. Following the final wash, the 
cells were re-suspended in 100 µL of BSA/PBS, and 1 µg of Alexa Fluor 488 
goat antihuman IgG (Invitrogen™) was added, followed by incubation for 1 h 
at 4°C. The cells were washed three times and analyzed using a FACSCalibur 




3.2.13 In vitro quantitative study of cellular uptake of micelles by 
microplate reader 
The in vitro cellular uptake of the micellar formulations was assessed with a 
microplate reader. After reaching confluence, cells were detached, counted 
and seeded in a 96-well black plate (Costar, IL,USA) at 2 × 10
4
 cells/well (0.1 
mL). After 24-h incubation, the medium was replaced by TPM and TPMC 
micelles suspensions with a concentration of 0.125 mg/mL. After 0.5 h, and 2 
h incubation, the micelle suspension was removed. Cells were washed twice 
with 1×PBS, and immersed in 50 mL of 0.5% Triton X-100 in 0.2 N NaOH 
solutions. After 15 min incubation under gentle shaking, the intensity of 
fluorescence was measured with a microplate reader at the excitation 
wavelength of 430 nm and the emission wavelength of 485 nm.   
3.2.14 In vitro qualitative study cellular uptake of micelles by confocal 
microscopy 
The in vitro qualitative study of cellular uptake of the micellar formulations 
was assessed by confocal laser scanning microscopy (CLSM). After reaching 
confluence, cells were detached, counted and seeded in an 8-well coverglass 
chamber (LAB-TEK, Nagle Nunc, IL, 280 USA) overnight. Then, the medium 
was replaced by TPM and TPMC suspension at a concentration of 0.125 
mg/mL and incubated for 2 h. The cells were washed twice with pre-warmed 
1×PBS and fixed with 70% ethanol for 20 min. Subsequently, the cells were 
washed twice with PBS and then the nuclei were counterstained by PI for 45 
min. The cells were washed again twice by 1×PBS and immersed in 1×PBS 
for confocal microscopic imaging. 
34 
 
3.2.15 In vitro cytotoxicity 
Cell lines were seeded in 96-well transparent plates (Costar, IL,USA) at 5 × 
10
3
 cells/well (0.1 mL) and after 12 h, the medium was replaced by micelles 
suspensions with fixed concentrations for 24 h. The micelles had been 
sterilized with UV irradiation overnight before the experiment. Cell viability 
was measured using MTT assay standard protocol, in which the optical density 












Figure 3.1  Schematic illustration of the formulation of docetaxel-loaded vitamin E TPGS micelles (TPD) and  






3.3 Results & Discussion 
3.3.1 Characterization of docetaxel-loaded vitamin E TPGS micelles 
pre- and post-cetuximab conjugation 
The size, size distribution and zeta potential measured by the dynamic light 
scattering (DLS) are shown in Table 3.1 and Figure 3.2, from which it can 
found that the mean sizes of docetaxel-loaded vitamin E TPGS micelles range 
from 10 nm to 20 nm. This result can also be observed from the field emission 
transmission electron microscopy (FETEM) images as shown in Figure 3.3. 
The mean size of the micelles conjugated with cetuximab increased to 25 nm. 
The finding that ligand conjugation increases the size of micelles agrees with 
the literature (Mi et al. 2011; Zhao et al. 2013). The polydispersity of all the 
micelles is less than 0.3, indicating a narrow size distribution.  It has been 
reported that micelles typically in the size range of 10–100 nm are suitable for 
drug delivery in cancer therapy (Blanco et al. 2009); such drug carriers 
enhance permeability and retention effect (EPR) to solid tumour (Maeda et al. 
2000). 
Surface charge of the micelles plays a significant role in both of its colloidal 
stability in suspension and interaction with cells. The zeta potential values for 
micelles generated from vitamin E TPGS with (TPD) or without (TPDC) are –
16 mV and –7 mV respectively, which exhibit a greater stability in PBS 
solutions at 4
o
C. The assessment of surface morphology of the micelles by 
FETEM (Figure 3.3) shows that the micelles have smooth surfaces and are 
spherical. FETEM also shows that cetuximab-conjugated micelles become 
much more adhesive (Figure 3.3B) than the non-conjugated ones (Figure 
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3.3A), which could be due to the attachment of the protein layer on the 
micelles.  
Table 3.1 Characterization of the TPD and TPDC micelles. Particle size, 
size distribution, zeta potential, and drug loading of the micelles with and 
without cetuximab conjugation. 





TPD 17.63 ± 0.2957 0.228 ± 0.02 -16.3 ± 1.61 58.15 ± 2.52 
TPDC 22.35 ± 2.170 0.266 ± 0.063 -7.13 ± 1.35 48.48 ± 1.75 
 
 
Figure 3.2 Particle size and size distribution of the micelles. A) Docetaxel-
loaded vitamin E TPGS micelles (TPD) and B) Cetuximab-conjugated 





Figure 3.3 Representative field emission transmission electron microscope 
(FETEM) images of the micelles. A) Docetaxel-loaded vitamin E TPGS 
micelles (TPD) and B) Cetuximab-conjugated docetaxel-loaded vitamin E 
TPGS micelles (TPDC). Scale bar = 20 nm. 
3.3.2 Optimization of the cetuximab antibody conjugation on micelles 
The amount of cetuximab conjugated on the micelle surface was optimized by 
varying the feeding concentration of the antibody during micelle preparation. 
In total, 5 different concentrations were used to prepare cetuximab-conjugated, 
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docetaxel-loaded micelles and the results are expressed in Table 3.2. It can be 
seen that the amount of the cetuximab conjugated to the micelles surface 
proportionally increases with the antibody concentration. A higher antibody 
concentration results in activation of more carboxylic groups by EDC and 
NHS to react with the free amine groups which are available abundantly on 
the surface of micelles, ultimately leading to in increased micellar sizes.  At 
0.0, 0.0082, 0.0376, 0.0840, 0.104 and 0.1329 mg of cetuximab per mg of 
micelles, the  micellar sizes were found to be  18.25 ± 2.084, 20.74 ± 0.9808, 
20.85 ± 2.160, 22.35 ± 2.170, 181.2 ± 31.90 and 288.4 ± 2.328  nm, 
respectively. The drastic increases in particle size at high antibody feeding 
concentrations could be due to the formation of layer-by-layer antibody 
conjugation where the outmost layer of the ligand shields the inner molecules, 
resulting in the equivalent of one layer of ligands and an inevitably increased 
particle size (Liu et al. 2010). Besides, an increase in ligand density on the 
micellar surfaces contributes to an abrupt reduction in surface charge due to 
the overall positive charge of cetuximab which have an isoelectric point of 
8.48 in UP water.  The decrease in zeta potential value as low as –2.98 ± 1.58 
and –1.04 ± 0.638 of TPDC-0.15 and TPDC-0.20 micelles will reduce the 
electrostatic repulsion between the micelles and thus promote particles 
aggregation. Therefore, as judged by the particle size, surface charge, drug 
loading, and the effect on cellular uptake efficiency, the TPMC-0.10 micelles 
should be chosen for the drug delivery system, which hereafter is defined as 
the cetuximab-conjugated docetaxel-loaded vitamin E TPGS micelles (TPDC).  
Besides varying the feed concentration of cetuximab, another way to control 
the amount of cetuximab conjugated to the micelles is by a proportional 
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change of the ratio of TPGS-NH2 over TPGS. The presence of more free 
amine groups on the surface of micelles and thus more cetuximab can be 
conjugated. Through this strategy, the desired amount of antibody can be 
conjugated to the micelles surface with desired size, surface charge and drug 




   Table 3.2 Characteristics of the TPDC micelles at various cetuximab feeding concentrations. Particle size,  









































0.418 ±  0.029 -1.04 ± 0.638 52.20 0.1329 
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3.3.3 Docetaxel drug loading to micelles 
Drug load is defined as the weight of drug (μg) per mg of the drug-loaded 
nanocarriers. The docetaxel loaded into the various micelles was measured 
using HPLC and the results are shown in Table 3.1 and Table 3.2, the 
docetaxel load for TPD and TPDC are 58.15 μg/mg and 48.48 μg/mg 
respectively. The loss of drug from micelles after the conjugation process can 
be explained by the repeated washing to remove excess amounts of EDC, 
NHS, and non-conjugated ligands and by the potential drug release from the 
micelles due to prolonged stirring.  The percentages of drug loss are 
disproportionate to cetuximab feeding concentrations and the micellar sizes, 
which are found to be 19.22 %, 19.42%, 13.87%, 11.97% and 7.26% for 
TPDC-0.01, TPDC-0.05, TPDC-0.10, TPDC-0.15 and TPDC-0.20, 
respectively. This is because an increase in cetuximab conjugation on the 
micelles surfaces results in a barrier which reduces the diffusion of drug 
outwards. Therefore, at a low feeding concentration, small micelles tend to 
lose more drugs than large micelles at a high feeding concentration.  
3.3.4 Surface chemistry 
The conjugation of cetuximab on the vitamin E TPGS micelles was fulfilled 
by a one-step carbodiimide coupling method with EDAc and NHS in aqueous 
phase (Figure 3.1), where the carboxylic groups on the antibody molecules 
were activated first and then reacted with the primary amine groups on the 
TPGS-NH2 chains to form amide bonds, thereby linking the antibody 
molecules to the micellar surface.  The surface chemistry of the docetaxel-
loaded vitamin E TPGS micelles pre- and post- cetuximab conjugation was 
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examined with X-ray photoelectron spectroscopy (XPS). The results are 
shown in Figure 3.4, where the graphs represent the micelles loaded with 
docetaxel pre- and post-cetuximab conjugation respectively and the inset 
highlights the signal at the position corresponding to the binding energy of N 
1s. The N 1s signal is undetectable before conjugation due to the small amount 
of N from the vitamin E TPGS polymer. However, cetuximab 
(C6484H10042N1732O2023S36) contains 1732 nitrogen atoms. Therefore, after 
conjugation, the appearance of the nitrogen peak indicates the presence of 
cetuximab on the micellar surface.  
 
Figure 3.4 Representative X-ray photoelectron spectroscopy (XPS) 
spectrum of wide scan spectrum and N 1s peaks (the inset) for the 
micelles. The appearance of the nitrogen peak indicates the presences of 
cetuximab on the TPDC micelles.  
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3.3.5 Flow cytometry analysis for EGFR expression of cell lines 
The anti-EGFR antibody (cetuximab) was used to analyze the levels of EGFR 
expression of six different cell lines. MDA-MB-468, MDA-MB-231 and HCC 
38 (Figure 3.5A-C) were classified as triple negative breast cancer (TNBC), 
MCF-7 and SK-BR-3 of ER/PR and HER2 (Figure 3.5D,E) as receptor-
positive breast cancer respectively and NIH3T3 (Figure 3.5F) as a fibroblast 
cell line.  The stained cells were analysed in a flow cytometry and the results 
are shown in Figure 3.5, with the dotted line representing the (untreated) 
control of each cell line and the solid line representing the significance of the 
fluorescent shift after treatment with the anti-EGFR antibody. This experiment 
showed that the intensity of fluorescence signal varied to a greater degree 
among all the triple negative breast cancer cell lines with the MDA-MB-468 
exhibiting the highest extent of EGFR expression on the cell surface, followed 
by the moderate EGFR expression in MDA-MB-231 and the lowest level 
EGFR expression in HCC38. This is in comparison to the fibroblast cell line 
NIH 3T3 and positive breast cancer cells, which exhibit normal expression of 
EGFR. Thus, MDA-MB-468 and MDA-MB-231 cell lines are frequently used 
as model cells of the triple negative breast cancer with EGFR overexpression. 
Correspondingly, MCF-7 and SK-BR-3 were used as model cell lines for 
ER/PR over-expression and HER2 over-expression respectively (Mi et al. 





Figure 3.5 Representative flow cytometry for EGFR receptor expression 
of various breast cancer cell lines. A) MDA-MB-468, B) MDA-MB-231, C) 
HCC38 , D) NIH 3T3, E) MCF-7 and F) SK-BR-3 cell lines. Dotted line 
represent the (untreated) control and solid line represent the fluorescent shift 
after treatment with the anti-EGFR antibody. Fluorescent intensity is represent 
by the Alexa Fluor 488 reading, Count represents the number of cell 
population 
 
3.3.6 In vitro drug release  
The in vitro drug release profiles of the docetaxel-loaded vitamin E TPGS 
micelles decorated with (TPD) and without (TPDC) cetuximab in PBS (pH 
7.4) for 240 h are shown in Figure 3.6. The drug release conforms to a 
biphasic profile with a small initial burst followed by a zero-order pattern. The 
initial burst for the first 12 h is found to be 45.79 ± 2.28% for TPD and 33.46 
± 1.67% for TPDC. The burst release could be due to the diffusion of 
docetaxel from the outer core of the micelles. Overall, both the micelles with 
and without ligand conjugation showed sustained and controlled release of the 
drug, where the cumulative drug release is  64.83 ± 3.24% for TPD and 54.31 
± 2.72 % for TPDC after  6 days. Overall, the drug release from TPDC is 
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slightly slower than that from TPD, as could be attributed to the presence of a 
ligand layer that functions as a barrier for drug release (Liu et al. 2010).  
 
Figure 3.6 In vitro accumulative drug release profile of TPD and TPDC 
micelles at pH=7.4. Drug release from TPD is indicated in green and that 
from TPDC in red. Data represent mean ± SD, n=3. One-way ANOVA 
compared to TPD, *p < 0.05 
 
3.3.7 In vitro cellular uptake 
3.3.7.1 In vitro cellular uptake: qualitative study 
Figure 3.7 shows confocal images of NIH3T3, SK-BR-3, MCF-7, MDA-MB- 
468, MDA-MB-231 and HCC38 cell lines after 2h incubation with the 
coumarin-6 loaded vitamin E TPGS micelles with (TPMC) and without (TPM) 
cetuximab conjugation. The green fluorescence obtained from the 
fluorescence isothiocyanate (FITC) channel represents TPM or TPMC 
whereas the red fluorescence obtained from the propidium iodide (PI) channel 




by green fluorescence, reflecting the entry of the micelles with and without 
cetuximab conjugation into the cytoplasm. The intensity of green fluorescence 
indicates the number of micelles internalized by the cells as all the images 
were taken under the same exciting laser intensity from the same confocal 
microscopy. The results demonstrate that the green fluorescence is more 
intense for the coumarin 6-loaded micelles with than for those without 
cetuximab conjugation, especially for MDA-MB-468 and MDA-MB-231 cells 
which overexpress EGFR. Thus, it can be concluded that the presence of 
cetuximab ligands on the micellar surface will enhance and facilitate the 
internalization of micelles into EGFR-overexpressing cells through receptor-
mediated endocytosis. However, for the cells with a low EGFR expression, 
there was no significant difference for the green fluorescence between TPMC 




Figure 3.7 Representative confocal laser scanning microscopy (CLSM) 
images depict the cellular uptake of the coumarin 6-loaded vitamin E 
TPGS micelles (2 h incubation). Green: FITC channels showing the green 
fluorescence from coumarin 6-loaded micelles distributed in cytoplasm. Red: 
PI channels showing the red fluorescence from propidium iodide stained 
nuclei. TPM show the cells incubated coumarin 6-loaded vitamin E TPGS 
micelles and TPMC for cetuximab-conjugated, coumarin 6-loaded vitamin E 





3.3.7.2 In vitro cellular uptake: quantitative study 
Cellular uptake of micelles by the triple negative breast cancer cells was 
further quantified by the fluorescent mode assessed by the microplate reader. 
It has been demonstrated in our earlier publication for cellular uptake of  
coumarin 6-loaded nanoparticles of biodegradable polymers that the surface 
density of the ligands on particles positively affects the efficiency of in vitro 
cellular uptake (Liu et al. 2010; Zhao et al. 2012). In this work, a series of 
vitamin E TPGS micelles with various antibody amounts conjugated on the 
surface were prepared. For simplicity, we denote the vitamin E TPGS micelles 
conjugated with cetuximab concentration of 0.0, 0.0356, 0.0822, 0.1076 and 
0.1304 mg per mg of the micelles by TPD, TPMC-0.05, TPMC-0.10, TPMC-
0.15 and TPMC-0.20 respectively according the feeding concentration of 
cetuximab 0.0, 0.05, 0.10, 0.15 and 0.20 mg/mL used in preparation of the 
micelles respectively. The same concentration of coumarin 6-loaded vitamin E 
TPGS micelles without or with cetuximab conjugation was incubated with the 
EGFR-overexpressing MDA-MB-468 cells   for 0.5 h and 2 h respectively. 
The results (shown in Figure 3.8) suggest that the intensity of fluorescence 
from the micelles increases with the amount of targeting ligand presence on 
the micellar surface. For example, after  the 0.5 h incubation, the cellular 
uptake of TPMC-0.05, TPMC-0.10, TPMC-0.15 and TPMC-0.20 are found to 
be 1.25-, 1.33-, 1.43- and 1.44-fold higher than that of  TPM, respectively; for 
the 2 h incubation, the cellular uptake is 1.46-, 1.83-, 1.90- and 1.92- fold 
higher than that of TPD, respectively. It is  noteworthy that the optimum 
cellular uptake of cetuximab conjugated micelles was achieved by TPMC-0.10 
and that no significant effect on cellular uptake was observed with further 
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increases of the amount of the conjugated ligand on the micellar surface. This 
could be due to the effects of particle size on cellular uptake (Win & Feng 
2005).  
 
Figure 3.8 Cellular uptake efficiency of the coumarin 6-loaded vitamin 
E TPGS micelles. The TPM and TPMC micelles were incubated on EGFR-
overexpressing MDA-MB-468 cells at various cetuximab feeding 
concentrations respectively at 37 ºC. Data represent mean + SE, n=6. 
Student’s t-test compared to 0.5 h, *p < 0.05. 
 
Since the TPMC-0. 10 micelles show optimum uptake for MDA-MB-468 cell 
lines, we thus wished to compare them with TPMC-0. 10 micelles. The 
TPMC-0. 10 micelles were employed to further evaluate the cellular uptake 
efficiency of the fibroblast cells (NIH 3T3), HER2-overexpressing breast 
cancer cells (SK-BR-3), ER- and PR-overexpressing breast cancer cells 
(MCF-7), and TNBC cells of high, moderate and low EGFR overexpression’s 
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(MDA-MB-468, MDA-MB-231 and HCC38). The results are depicted in 
Figure 3.9. After the 0.5 h incubation, the TPMC-0.01 micelles resulted in 
0.95-, 1.42-, 0.97-, 1.72-, 1.33- and 1.29-fold higher cellular uptake and, after 
the 2 h incubation, 0.81-, 1.22-, 1.03-, 1.56-, 1.83- and 1.17- fold higher 
cellular uptake than the TPM for NIH 3T3, SK-BR-3, MCF-7, MDA-MB-231, 
MDA-MB-468 and HCC38, respectively. This shows that cetuximab 
conjugation has a significant positive effect on the EGFR-overexpressing 
TNBC cancer cells lines such as MDA-MB-468 and MDA-MB-231. Besides 
that, a significant uptake of TPMC was observed for non-EGFR cells (SK-BR-
3) after incubation with targeted micelles which could be due to micellar 
internalisation via membrane-mediated passive transport (Master, 2013). 
However, no significant effect was observed for the other cell lines that do not 
overexpress EGFR. The enhanced cellular uptake of cetuximab-conjugated 
micelles can be attributed to receptor-mediated endocytosis (RME) 




Figure 3.9  Cellular uptake efficiency of the TPM and TPMC micelles on 
NIH3T3, SK-BR-3, MCF-, MDA-MB-468, MDA-MB-231 and HCC38.The 
TPM and TPMC micelles was incubated A) 0.5 h and B) 2 h at 37 ºC . Data 




3.3.8 In vitro cytotoxicity 
The efficacy of the docetaxel drug in triple negative breast cancer treatment 
was assessed by the in vitro cytotoxicity study. The study was conducted on 
various breast cancer cell lines including breast cancer cells MCF-7 of ER and 
PR positive, breast cancer cells SK-BR-3 of HER2 overexpression, TNBC 
cells MDA-MB-468, MDA-MB-231 and HCC38 cells of high, moderate and 
low EGFR expression, respectively. Figure 3.10 illustrates the cell viability of 
these cell lines treated with the docetaxel-loaded vitamin E TPGS micelles 
with (TPDC) and without (TPD) cetuximab conjugation after 24 h treatment, 
which was assessed in comparison with that of the Taxotere® (Dox) drugs at 
various concentrations. It can be seen that higher cell viability for the triple 
negative breast cancer cell lines indicates lower therapeutic effects in 
comparison with the other types of breast cancer cells such as HER2-
overexpressing SK-BR-3 cells and ER- and PR-overexpressing MCF-7 cells. 
This suggests that docetaxel is less effective for TNBC cells than for other 
types of breast cancer cells (De et al. 2009; Isakoff 2010). The advantage of 
nanomedicine for TNBC treatment can be observed in Figure 3.10, where the 
viability of the various cell lines treated with the docetaxel-loaded vitamin E 
TPGS micelles without cetuximab conjugation (TPD). It is noteworthy that the 
docetaxel-loaded micelles have higher cytotoxicity for SK-BR-3, MCF-7 and 
TNBC cells when compared with the free drug formulation, i.e. Dox. This 
could be due to the advantages of nanomedicine, including the high drug 
transportation efficiency across the cell membrane by endocytosis, the 
controlled release nature of the micellar formulation and the ability of the 
nanocarrier to overcome multidrug resistance (MDR). 
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The docetaxel-loaded vitamin E TPGS micelles were further conjugated with 
cetuximab (TPDC) for targeted therapy. It can be seen from Figure 3.10 that 
lower cell viability was observed for TPDC than for TPD (without cetuximab 
conjugation) and for Dox at the same drug concentration. The finding can be 
rationalised by the fact that cetuximab can bind to the EGFRs overexpressed 
by cancerous cells, thereby enhancing the uptake of the micelles into the cells 
and augmenting the effectiveness of docetaxel. The efficacy of TPDC, TPD 
and Dox can be quantitatively analyzed by IC50, which is defined as the drug 
concentration needed to kill 50% of the cells in a designated time period, for 
example 24 h,  as listed in Table 3.3. Notably, the presence of cetuximab in 
the micellar formulation has effectively killed the EGFR-overexpressing 
TNBC cells.  For example, for MDA-MB-468 cells cultured with the TPDC, 
TPD and Dox formulations, the IC50 values are found to be 35.26, 1.12 and 
0.1715 µg/mL; for MDA-MB-231 cells likewise treated, the values are found 
to be 15.53, 1.52 and 0.0694 µg/mL. This indicates that TPDC formulation  
require lower drug concentrations to achieve the same in vitro therapeutic 
efficiency, which is  205.60- and 223.78-fold more efficient than Dox for 
MDA-MB-468 and MDA-MB-231, respectively. However, the TPDC 
formulation also resulted in certain degree in a lower IC50 value than TPD for 
the positive breast cancers. Next to examine whether the cetuximab antibody 
induced cell death, we therefore exposed EGFR-overexpressed MDA-MB-468 
TNBC cells and non-EGFR MCF-7 cells with cetuximab for 24 h. Despite 
being exposed to a very high concentration, we did not observe any significant 










Figure 3.10 The diagram presents the cell viability of MCF-7, SK-BR-3, 
MDA-MB-231, HCC38 and MDA-MB-468 cells incubated with Dox, TPD 
and TPDC for 24 h. The cells were treated with various drug concentrations 
0.025, 0.25, 2.5 and 5 µg/mL. Data represents mean + SE, n=6. Student’s t-








Figure 3.11 Cetuximab treatment did not elicit cytotoxicity on EGFR-
overexpressed MDA-MB-468 cells. The MCF-7 and MDA-MB-468 cells 
were treated with various cetuximab antibody concentrations for 24 h. Data 
represents mean + SE, n=3. 
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Table 3.3 The IC50 values of the docetaxel-loaded micelles. Cytotoxicity of the Dox in vitamin E TPGS micelles with or without cetuximab 









Positive breast cancers Triple negative breast cancers 











Dox (µg/mL) 1.81 1.136 35.26 15.53 6.27 
TPD (µg/mL) 0.9134 0.5994 1.116 1.52 1.001 
TPDC 
(µg/mL) 




The formulation with or without the optimized ligand concentration on the 
micellar surface was selected to elucidate the advantages of the vitamin E 
TPGS micellar formulation and the targeting effects of cetuximab for the 
TNBC treatment. It was found that the TNBC cells exhibited a greater degree 
of drug resistance than the ER/PR or HER2 positive breast cancer cells. 
Interestingly, the drug resistance can be greatly attenuated by the vitamin E 
TPGS micellar formulation and further by cetuximab conjugation to target the 
EGFR-overexpressing TNBC cells with regard to the IC50, the drug can be 
205.60- and 223.78-fold more effective for MDA-MB-468 and MDA-MB-231 
cells, respectively. However, one shortcoming with the use of the IC50 is that 
such values are determined from single-cell in vitro studies and may not be 
accurate for the determination of therapeutic efficacy in clinical settings. 
Therefore, in order to gain a better understanding on targeted based delivery 
systems, we tested the efficacy of our targeted micelles in a more complex 





Chapter 4 In vitro co-culture of cetuximab conjugated vitamin 
E TPGS against EGFR-overexpressing triple negative breast 
cancer cells 
4.1 Introduction 
A typical in vitro study of targeted anticancer drug delivery is based on single 
cells grown as a monolayer. A significant of this approach is that it does not 
recapitulate the true targeted capability of a nanomedicine. The IC50 values 
determined from such in vitro studies may not be accurate in predicting the 
therapeutic efficacy in clinical settings. Therefore, in order to gain a better 
understanding on targeted based delivery systems, more complex systems such 
as the in vitro co-culture model and the in vivo model should be used for 
proof-of-concept evaluation. In Chapter 4, to determine cetuximab-mediated 
EGFR targeting specificity, we co-cultured two different cells named EGFR-
overexpressing MDA-MB-231 and non-EGFR-expressing MCF-7 cells to 
compare their competitive uptake of various micellar formulations. 
4.2 Materials & Methods 
4.2.1 Materials 
 1,10-dioctadecyl-3,3,30,30-tetramethylindodicarbocyanine perchlorate (DiD, 
D-307), CellTracker™ Green CMFDA (C2925), Tali® apoptosis kit 
(A10788), fetal bovine serum (FBS) and penicillin-streptomycin solution were 
provided by Invitrogen. 4,6-diamidino-2-phenylindole (DAPI) was purchased 
from Sigma-Aldrich (USA). Dulbecco’s Modified Eagle’s Medium (DMEM) 
were purchased from Thermo Scientific (USA). MCF-7 and MDA-MB-231 
was provided by American Type Culture Collection (ATCC, USA).  
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4.2.2 Preparation of vitamin E TPGS micelles 
Docetaxel-loaded micelles were prepared according to solvent casting method 
as mentioned in chapter 3. Briefly, docetaxel (2 mg) or DiD dye (0.1 mg) was 
used to synthesis the vitamin E TPGS micelles. Herein, we denote the 
docetaxel-loaded vitamin E TPGS micelles without and with cetuximab as 
TPD and TPDC, respectively, and the DiD-loaded micelles without and with 
cetuximab as TPF and TPFC, respectively. 
4.2.3 Cell culture 
MCF-7, and MDA-MB-231 cells were grown in DMEM medium 
supplemented with 10 % v/v FBS and 1 % v/v penicillin-streptomycin 
solution. All cell lines were grown at 37 °C in the presence of 5 % CO2. 
4.2.4 Co-culture for in vitro cellular uptake 
Qualitative study of cellular uptake of the micellar formulations was assessed 
by the confocal laser scanning microscopy (CLSM). After reaching 
confluence, MCF-7 and MDA-MB-231 cells were detached and counted. To 
distinguish MCF-7 cells from MDA-MB-231, the latter were labelled with 
CellTracker™ Green CMFDA dye prior to seeding them. The cells then were 
mixed at ratio 1:1 and seeded in an 8-well cover glass chamber slide (LAB-
TEK, USA) overnight. Afterwards, the medium was replaced by DiD dye 
loaded micelles suspension at concentration of 0.125 µg/mL and incubated for 
2 h. The cells were washed twice with pre-warmed 1 × PBS and fixed with 70 
% ethanol for 20 min. After that, the cells were washed twice with PBS and 
then the nuclei were counterstained by DAPI for 45 min. The cells were 
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washed again twice by 1 × PBS and immersed in 1 × PBS for confocal 
microscopic imaging. 
Quantitative study of cellular uptake of the micellar formulations was assessed 
by the flow cytometry. After reaching confluence, MCF-7 and MDA-MB-231 
cells were detached, counted and seeded at ratio of 1:1 on 24-well black plates 
(Costar, USA). After 12 h, DiD dye loaded micelles suspension at 
concentration of 0.125 µg/mL and incubated for 2 h. After 2 h, the micelles 
suspension was removed and then washed twice with 1 × PBS. The cellular 
uptake was measured using FACSCalibur with CellQuest software (BD 
Biosciences, USA). The data were derived from a minimum of 10,000 events 
per sample measurement. Each sample was tested in triplicates.   
4.2.5 Co-culture for in vitro cytotoxicity 
MDA-MB-231 and MCF-7 cell lines were seeded on 24-well transparent 
plates (Costar, USA) at a 1:1 ratio. To distinguish MCF-7 cells from MDA-
MB-231, the latter were labelled with CellTracker™ Green CMFDA dye prior 
seeding them on 24-wells plate. After 12 h, the medium was replaced by 
micellar suspensions with 2.5 µg/mL of docetaxel (Dox, TPD or TPDC) for 24 
h. The micelles were sterilized with UV irradiation overnight before the 
experiment. The dead cells were stained with PI staining and analyzed by 
using FACSCalibur with CellQuest software (BD Biosciences, USA). The 
data were derived from a minimum of 10,000 events per sample measurement. 
Each sample was tested in triplicates.   
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Figure 4.1: Schematic cartoon showing the co-culture experimental setup 
4.3 Results and discussion 
4.3.1 In vitro co-culture cell uptake  
To determine cetuximab-mediated EGFR targeting specificity, we co-cultured 
MDA-MB-231 (EGFR-overexpressing) with MCF-7 (non EGFR-
overexpressing) cancerous cells at the same cell numbers and compared their 
competitive uptake of the various micellar formulations. The in vitro micelle 
uptake in co-culture system of MDA-MB-231 and MCF-7 was analysed by 
confocal laser scanning microscopy (CLSM). All cells’ nuclei were labelled 
blue with DAPI nucleus stain. To distinguish MCF-7 cells from MDA-MB-
231, the latter were labelled “green” with CellTracker™ Green CMFDA dye. 
The micelles were labelled with red fluorescence dye (DiD). Figure 4.2  
illustrates that higher yellow fluorescence (green overlapping with red) 
was detected in the targeting cetuximab-conjugated micelle (TPFC) 
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treated group. Conversely, a lower extent of uptake was observed for the 
non-targeting micelles (TPF) on the MDA-MB-231 cells compared with 
MCF-7. This suggests that cetuximab conjugated to micellar surfaces 
enhanced the affinity of micelles to EGFR-positive cells (Doody et al. 
2007). 
 
Figure 4.2 Cetuximab-conjugated DiD-loaded vitamin E TPGS micelles, 
(Targeted micelles, TPFC) shows a higher uptake on the EGFR-
overexpressing MDA-MB-231cells in co-cultures of MCF-7 and MDA-
MB-231 breast cancer cells. Confocal laser scanning microscopy (CLSM) 
images show targeted micelles could enhance the cellular uptake in MDA-
MB-231cells after 2 h of incubation with DiD-loaded micelles (red). MDA-
MB-231 cells were stained green with CellTracker™ green CMFDA, while 
the nuclei of MDA-MB-231 and MCF-7 cells were visualized by DAPI 
staining (blue). The merged red and blue channels show the uptake of micelles 
by MCF-7 whereas the merged channels of red, green and blue show the 
uptake of micelles by MDA-MB-231 cells. Scale bar = 30 µm. 
 
To further support these results, the uptake of targeting micelles in co-culture 
was quantified by flow cytometry. The MDA-MB-231 cells were stained with 
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CellTracker™ Green CMFDA dye in order to distinguish both cell types and 
to allow an individual analysis of micelle internalisation. Figure 4.3 shows 
that micelle internalisation by the EGFR-overexpressing MDA-MB-231 cells 
increased by 1.7-fold whereas that by the non EGFR-overexpressing MCF-7 
cells decreased by 0.3-fold after the incorporation of cetuximab in the micellar 
formulation; this finding concurs with observations from fluorescence 
imaging.   
 
Figure 4.3 Quantitative analysis of micelles shows that MDA-MB-231 cells 
are more efficient in the uptake of TPFC micelles in co-culture. Data 
represent mean ± SD, n = 3. Student’s t-test compared to MCF-7, *p < 0.05   
4.3.2 In vitro co-culture cytotoxic effects 
The cytotoxic effect of the docetaxel formulations in in vitro co-culture 
was assessed by flow cytometry. Figure 4.4 illustrates the extent of cell 
death after treatment with 2.5 µg/mL of free docetaxel (Dox), TPD and 
TPDC for 24 h. The MDA-MB-231 cells were stained with CellTracker™ 
Green CMFDA dye in order to distinguish both cell types and to allow an 
individual cell death analysis. The extents of cell death observed with Dox, 
TPD and TPDC for MCF-7 were found to be 2.88-, 132- and 48-fold 
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respectively; those for MDA-MB-231 were 3.75-, 275-, and 368-fold (Figure 
4.4). For EGFR-overexpressing cells, a greater extent of dead cells was 
observed in treatment group treated with cetuximab-conjugated docetaxel-
loaded micelles (TPDC) compared with the group treated with free drug (Dox) 
and non-targeting docetaxel-loaded micelles (TPD). However, for non EGFR-
overexpressing cells, a larger extent of cell death was observed in the 
treatment group treated with the non-targeting micelles formulation compared 
with the group treated with targeting micelles. This could be attributed to the 
presence of cetuximab on the surface of micelles that facilitates micelle 
internalization into the EGFR-expressing cells via receptor-mediated 
endocytosis (Doody et al. 2007; Arvizo et al. 2013). This results in a greater 
degree accumulation of docetaxel in MDA-MB-231, thereby augmenting 




Figure 4.4 The cytotoxicity study shows higher killing effects on MDA-
MB-231 cells after treated with 2.5 µg/mL cetuximab-conjugated 
docetaxel-loaded vitamin E TPGS micelles (TPDC) for 24 h. Normalized to 




The co-culture in vitro studies using EGFR-overexpressing TNBC cells 
(MDA- MB-231) and non-EGFR-overexpressing positive breast cancer cells 
(MCF-7) strongly suggests that our targeted micellar formulation increases the 
uptake by MDA-MB-231 cells. This further enhanced the killing effect on 
EGFR-overexpressing TNBC cells compared with MCF-7. This could be 
attributed to the presence of cetuximab on the surface of micelles that 
facilitates micelle internalization into the EGFR-expressing cells via 
receptor-mediated endocytosis. These findings provide a guideline for further 










Chapter 5 In vivo proofs of concept that cetuximab-
conjugated vitamin E TPGS micelles increases efficacy of 
delivered docetaxel against triple negative breast cancer 
5.1 Introduction 
In chapter 3, we have demonstrated that TNBC is highly resistant towards 
conventional chemotherapy treatment; however it was observed that the 
delivery of docetaxel using vitamin E TPGS micelles could increase 
sensitivity of TNBC cells (MDA-MB-468, MDA-MB-231 and HCC 38) 
thereby inducing a higher in vitro cytotoxic effect. However, the 
biodistribution of the targeted vitamin E TPGS nanocarrier and the anti-
tumour activity in in vivo models have not been reported. The aim of this work 
was to explore the biodistribution and anti-tumour efficacy of cetuximab-
based targeted drug delivery system for TNBC in a xenograft model. In this 
study, we have synthesized cetuximab-based targeted micelles as a nanocarrier 
using D-α-tocopheryl polyethylene glycol succinate (vitamin E TPGS) for 







tetramethylindodicarbocyanine perchlorate).  The real time in vivo 
biodistribution and tumour targeting ability of the targeted micelles after 
intravenous injection were studied by non-invasive IVIS® imaging system. 
The anti-tumour effects of the vitamin E TPGS, docetaxel-loaded targeted and 
non-targeted vitamin E TPGS micelles were evaluated using the TNBC 
xenograft model, and compared with FDA-approved Taxotere® (Dox) which 
is used commercially in clinical studies.  
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5.2 Materials & Methods 
5.2.1 Materials 
Matrigel was purchased from BD Biosciences (USA). 1,10-dioctadecyl-
3,3,30,30-tetramethylindodicarbocyanine perchlorate (DiD, D-307). Fetal 
bovine serum (FBS) and penicillin-streptomycin solution were provided by 
Invitrogen. Dulbecco’s Modified Eagle’s Medium (DMEM). TNBC MDA-
MB-231/Luc cells were purchased from Cell Biolabs (USA). 
5.2.2 Preparation of vitamin E TPGS micelles 
Docetaxel-loaded micelles were prepared according to solvent casting method 
as mentioned in chapter 4. Herein, we denote the docetaxel-loaded vitamin E 
TPGS micelles without and with cetuximab as TPD and TPDC, respectively, 
and the DiD-loaded micelles without and with cetuximab as TPF and TPFC, 
respectively. 
5.2.3 Cell culture 
MDA-MB-231/Luc cells were grown in DMEM medium supplemented with 
10 % v/v FBS and 1 % v/v penicillin-streptomycin solution and grown at 37°C 
in the presence of 5 % CO2. 
5.2.4 Animal study 
Immunodeficient mice (CB17 SCID), 6-8 weeks of age (Female, 20–22 g) 
were purchased from In vivos (Singapore). All animal experiments were 
performed in compliance with protocol 097/10 approved by the Animal Use 
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and Care Administrative Advisory Committee at the National University of 
Singapore.  
5.2.4.1 Triple negative breast cancer models development 
Subcutaneous tumours were established by injecting 1×10
6
 MDA-MB-
231/Luc cells, which were dispersed in a 100 μL of 5 mg/mL Matrigel in PBS, 
at the right forelimb of the mice. The tumours were allowed to grow to reach 
tumour volumes of 100–500 mm3. 
5.2.4.2  Biodistribution by fluorescent imaging 
The biodistribution of DiD dye (F), non-targeting micelles (TPF) and targeting 
micelles (TPFC) was studied by fluorescent imaging. For imaging, the mice 
were divided into 3 groups with 3 mice in each group (n = 3). When the 
tumour volume reached approximately 500 mm
3
, the mice were subjected to 
intravenous injection of 50 nM of DiD dye (dissolved in DMSO), TPF or 
TPFC micelles in 100 µL of PBS via the tail vein. After injection, the mice 
were anaesthetized and scanned using Xenogen IVIS Spectrum imaging 
system coupled with cool CCD camera (Xenogen,  USA)  at an excitation 
wavelength of 620 nm and an emission wavelength of 710 nm at different time 
points (2, 6, 12, and 24 h). 
 After 24 h of in vivo imaging, the mice were anesthetized and their tumours 
and organs were harvested, which were then imaged with Xenogen IVIS. The 
images and measurements of fluorescence signals were acquired and analysed 
with the Xenogen live imaging software version 4.2. The signals were 
quantified as average fluorescent signals per cm
2 
i.e., radiant efficiency. The 
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semi-quantitative fluorescence (arbitrary unit) was calculated by drawing the 
region of interest (ROI) of different organs. The location of tumours in mice 
was monitored via the tumour cells’ luciferase expression as detected with 
non-invasive bioluminescence imaging using IVIS imaging system. Briefly, 
150 mg/kg of D-luciferin was introduced via intraperitoneal injection and 
bioluminescence images were obtained at 15 min of post luciferin injection 
using IVIS at an emission wavelength of 560 nm. 
5.2.4.3 In vivo therapeutic study 
Treatments were started when the tumour volume reached 200–300 mm3 in 
the CB17 SCID mice and the day on which the treatment started was 
designated as Day 0. The mice were divided into 5 groups with 5 mice in each 
group (n = 5). Mice were subjected to intravenous administration of Taxotere
®
 
(Dox), vitamin E TPGS micelles without drug (TP), docetaxel-loaded vitamin 
E TPGS micelles (TPD) and cetuximab-conjugated docetaxel-loaded vitamin 
E TPGS micelles (TPDC) formulation on Days 0, 3, 6, 9 and 12. All the drug 
formulations were given at the dose of 2 mg/kg. The mice in control group 
were administered only PBS. Animals were sacrificed when the implanted 
tumour volume reached 2000 mm
3 
according to the protocol. In addition to 
calliper measurement, the tumour responses were also monitored by non-
invasive bioluminescence imaging for luciferase expression using IVIS 
imaging system. Briefly, 150 mg/kg of D-luciferin was introduced via 
intraperitoneal injection and bioluminescence images were obtained at 15 min 
of post luciferin injection using IVIS at an emission wavelength of 560 nm. 
The images and measurements of bioluminescence signals were acquired and 
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analysed with the Xenogen live imaging software version 4.2. The signals 
were quantified as average bioluminescence signals per cm
2
 i.e., radiance. The 
semi-quantitative bioluminescence (arbitrary unit) was calculated by drawing 
the ROI around tumour areas enclosing emitted signals. On the last day of the 
treatment, after the bioluminescence imaging, the mice were sacrificed and 
their tumours were immediately harvested and weighed. The body weight of 
the mice had been monitored throughout the study.  
5.2.5 Statistical analysis 
Statistical analysis was performed by Student’s t-test for the two groups, and 
one-way ANOVA for multiple groups. All results were expressed as the mean 
± standard deviation (SD) unless otherwise noted. A value of p < 0.05 was 




5.3 Results and discussion 
 
Figure 5.1 Schematic cartoon showing the in vivo experimental setup. 
 
5.3.1 Characterization of docetaxel-loaded micelles and DiD-loaded 
micelles before and after cetuximab conjugation 
Micelles groups were prepared by using a procedure discussed in our previous 
chapter 3. The sizes of TPD and of TPDC were registered in a narrow 
distribution that ranges from 17 to 22 nm, as determined by dynamic light 
scattering (DLS) (Table 5.1). The addition of cetuximab (0.55 nmol/mg) to 
the surface of micelles resulted in slight increases in size compared with the 
non-targeting micelles. One of the advantages of micelles as drug carriers is 
their size (10–100 nm) which is bigger than the free drug molecules (1 nm). 
Thus, the nanocarrier protects the drugs from the otherwise immediate renal 
clearance, thereby increasing the circulatory half-life of drugs and facilitating 
the delivery through the leaky vasculature in solid tumours (Cabral et al. 2011; 
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Matsumura & Maeda 1986; Muthu et al. 2015). Table 5.1 shows the zeta 
potential for all the micelles as being negatively charged on the surface of both 
the TPD and TPDC. The negatively charged micellar system provides 
colloidal stability in the blood and facilitates cellular uptake via endocytosis 
(Kim et al. 2014; Win & Feng 2005; Honary & Zahir 2013). In addition, the 
PEG molecules on micellar surfaces enhance evasion of the immune system 
and hence decrease the loss of nanocarriers due to accumulation in the 
mononuclear phagocytic system (MPS) located in organs such as liver and 
spleen. These features improve the targeting efficacy of nanocarriers into 
tumours and minimize systematic toxicity (Oh & Park 2014; Feng 2011). The 
efficacy of the targeting micelles as a nanomedicine for TNBC was studied in 
vivo, as shown in Figure 5.1.   
Table 5.1 Characterization of micellar formulation used in in vivo study 
 
5.3.2 In vivo biodistribution of micelles by fluorescence imaging 
In vivo biodistribution and tumour-targeting characteristics of DiD dye (F), 
TPF, TPFC were observed using real-time fluorescence IVIS imaging system 
in mice bearing the subcutaneous MDA-MB-231/Luc cancer xenograft. The 
mice were subjected to intravenous injection with 50 nM of DiD dye, TPF or 
TPFC via the tail vein. Substantial contrast between tumours and normal tissue 
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was observed from 2 to 24 h post injection (Figure 5.2). Bioluminescence 
imaging was performed to identify the location of tumours in mice. For the 
targeting micelles (TPFC), fluorescence imaging depicts that they 
accumulated in tumours immediately after the administration of the micelles. 
The fluorescence signal gradually increased up to 12 h at the tumour site and 
sustained for up to 24 h, reflecting the increases in TPFC micelles in MDA-
MB-231/Luc cells. In comparison, for the non-targeting micelles (TPF), the 
fluorescence signal was evenly distributed all over the body of the mice. Only 
a slight increase in fluorescence at the chest area was observed after 24 h post-
injection, reflecting the moderate uptake of micelles by the tumour. There was 
no obvious contrast in fluorescence intensity for the free DiD dye, thereby 
eliminating the possibility of tumour-targeting effect facilitated by DiD dye 
alone. This study demonstrates that the immediate uptake of micelles by  
tumour tissues could be due to effectiveness of micelles to retain their 
structure in the systematic circulation before penetrating into tumours through 
the leaky vasculature (Swami et al. 2012; Setyawati et al. 2013). Besides that, 
the targeting micelles preferentially accumulated in tumours compared with 
normal tissues at a shorter time due to the strong affinity of cetuximab towards 
EGFRs on the MDA-MB-231/Luc cells which aided in the uptake of the 





Figure 5.2 Micelles TPFC facilitate the uptake of micelles into EGFR-
overexpressing MDA-MB-231/Luc tumours-bearing SCID mice. Whole-
mouse imaging (excitation/emission: 620/710 nm) study depicts the immediate 
uptake of TPFC micelles after intravenous injection in MDA-MB-231/Luc 
tumours-bearing SCID mice. The mice were subjected to intravenous injection 
of 50 nM of free DiD dye (F), with DiD-loaded vitamin E TPGS micelles 
(TPF) or with cetuximab-conjugated DiD-loaded vitamin E TPGS micelles 
(TPFC). The locations of the MDA-MB-231/Luc tumours were determined 
with bioluminescence by intraperitoneal injection of 150 mg/kg luciferin (left 
panel). 
 
For the biodistribution of these micelles after 24 h, the animals were sacrificed 
and the tumours and some major organs were excised for ex vivo fluorescence 
imaging using the IVIS imaging system. Figure 5.3 and Figure 5.4 show that 
TPF and TPFC micelles accumulated mainly in tumour tissues, which 
exhibited strong fluorescence intensity, about 3.4- and 10.8-fold higher, 
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respectively, than the free DiD dye, indicating the tumour-targeting ability of 
the micellar formulations. It is also noteworthy that the higher accumulation of 
micelles in the liver can be attributed to the presence of Kupffer cells which 
tend to accumulate substances eliminated by the mononuclear phagocyte 
system from the blood (Sadauskas et al. 2007; Longmire et al. 2008).   
 
Figure 5.3 Fluorescence imaging of excised tumours and organs indicated 
a strong intensity of TPFC at MDA-MB-231/Luc tumours. F= DiD dye; 
TPF= DiD-loaded vitamin E TPGS micelles; TPFC = cetuximab-conjugated 





Figure 5.4 Quantitative analysis of fluorescence intensities of tumours and 
organs from sacrificed mice.  The TPFC micellar formulations accumulated 
highly in the tumour and the liver. Normalized to free DiD dye. F= DiD dye; 
TPF= DiD-loaded vitamin E TPGS micelles; TPFC = cetuximab-conjugated 
DiD-loaded vitamin E TPGS micelles. Data are means ± SD, n = 3. Student’s 
t-test compared to control, *p < 0.05.  
 
5.3.3 In vivo therapeutic effect of the micelles 
The therapeutic efficacy of micellar formulations after intravenous 
administration was evaluated in mice bearing the subcutaneous MDA-MB-
231/Luc cancer xenograft. The mice received injection of either saline or 2 
mg/kg of one of the following formulations: Taxotere
®
 (Dox), vitamin E 
TPGS micelle (TP), non-targeting (TPD) and targeting micelles (TPDC) on 
Days 0, 3, 6, 9 and 12. Bioluminescence imaging was carried out pre- and 
post-treatment in order to assess changes in tumour size (Figure 5.5). These 
bioluminescence images evidently showed that tumour growth was inhibited 
in the targeting micelles, TPDC group. The total emitted bioluminescence 
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intensity was measured (Figure 5.6), where the ROI data indicated 
bioluminescence intensity between Days 0 and 15 of the control, Dox, TP, 
TPD and TPDC micelles treatment are found to be 18.2-, 15.2-, 16.4-, 2.4- and 
1.02-fold, respectively. It is  noteworthy that docetaxel formulated in the 
targeting  micelles (TPDC) exhibited a greater degree of Day growth 
inhibition after 15 days of treatment compared with non-targeting micelles 
(TPD) and with free docetaxel. Although the non-targeting micellar 
formulation shows significant decreases in Day growth compared with 
docetaxel and saline, it is still less effective than the targeting micelles. This 
suggests the capability of the TPDC micelles of facilitating better drug 
delivery to the tumour cells compared with the TPD formulation. However, 
Dox nonetheless resulted in slight decreases in the bioluminescence intensity 





Figure 5.5 In vivo study of anti-tumour efficacy evidently shows tumour 
growth inhibition by targeting micelles TPDC. The mice were administered 
intravenously with saline (control), Dox, TP, TPD and TPDC on Days 0, 3, 9 
and 12 when the tumour volume reached about 200–300 mm3 in the CB17 
SCID mice. The initial and final sizes of MDA-MB-231/Luc tumour were 
determined with bioluminescence using Xenogen IVIS imaging system by 
intraperitoneal injection of 150 mg/kg luciferin. Dox = Taxotere
®
; TP = 
vitamin E TPGS micelle without drug; TPD = docetaxel-loaded vitamin E 






Figure 5.6 The semi-quantitative bioluminescence analysis indicates that 
tumours in TPDC-treated mice were of a smaller size. Normalized to 
control. Dox = Taxotere
®
; TP = vitamin E TPGS micelle without drug; TPD = 
docetaxel-loaded vitamin E TPGS micelles; TPDC = cetuximab-conjugated 
docetaxel-loaded vitamin E TPGS micelles. Data are means ± SD, n = 5, 
Student’s t-test compared to control, *p < 0.05. 
 
All the treatment groups were well-tolerated as no drastic body weight loss 
was observed for all the animals throughout the study (Figure 5.7). At the end 
of the study, i.e. after 15 days of treatment, the tumours were excised and 
weighed (Figure 5.8 and Figure 5.9). For non-targeting (60%) and targeting 
micelles (80%), a remarkable reduction in tumour weight was observed 
relative to the control; only slight reduction, however, was observed for 




Figure 5.7 Body weight of the tumour-bearing mice before and after the 
treatment shows no significant weight loss. Data are means ± SD, n = 5, 
One-way ANOVA compared to control, *p < 0.05. Dox = Taxotere
®
; TP = 
vitamin E TPGS micelle without drug; TPD = docetaxel-loaded vitamin E 







Figure 5.8 Tumour weight from different treatment groups were 
measured after the mice were sacrificed on the 15th day. The measurement 
shows a significantly lower tumour weight for TPD- and TPDC-treated 
groups. Data are means ± SD, n = 5. Student’s t-test compared to control, *p < 
0.05. Dox = Taxotere
®
; TP = vitamin E TPGS micelle without drug; TPD = 
docetaxel-loaded vitamin E TPGS micelles; TPDC = cetuximab-conjugated 
docetaxel-loaded vitamin E TPGS micelles. 
 
 
Figure 5.9 Image of MDA-MB-231/Luc tumours excised from the 
respective treatment groups after the 15th day. Dox = Taxotere
®
; TP = 
vitamin E TPGS micelle without drug; TPD = docetaxel-loaded vitamin E 
TPGS micelles; TPDC = cetuximab-conjugated docetaxel-loaded vitamin E 





Based on the results of the in vivo study, the targeted micelles accumulated in 
tumour immediately after the micelles were intravenously injected and were 
retained for at least 24 hours. The successful delivery of docetaxel into tumour 
by the targeted micelles (TPDC) exhibited a greater degree of tumour growth 
inhibition than Taxotere® after 15 days of treatment. The administration of 
free vitamin E TPGS micelles caused no toxicity on the tumour, attesting to 
the biocompatibility of this nanocarrier.  In addition to the in vivo study, we 
further performed ex vivo studies of the tumours in order to elucidate the 
behaviours of the cancerous cells after treatment with different treatment 










Chapter 6 Ex vivo proofs of concept that cetuximab-
conjugated vitamin E TPGS micelles increases efficacy of 
delivered docetaxel against triple negative breast cancer 
6.1 Introduction  
The typical flow of experimentation when working with an anticancer drug 
carrier system begins with the characterization of the system in cancer cell 
cultures, followed by a proof-of-concept experiment in the animal. In in vitro 
cell cultures, many fundamental and hypothesis-driven questions involving the 
characterizations and mechanisms of action of a given drug carrier system 
could be formulated. Subsequently, the drug carrier system is introduced into 
the animal cancer model. While this flow is essential as part of the pre-clinical 
process, there is an often untested, critical assumption in this line of thought: 
the mechanistic information gleaned from the in vitro cell culture studies is 
assumed to reflect that of an animal model. Therefore, it may be unsurprising 
that few studies go beyond the proof of concept or efficacy evidence.  
There is therefore a need to rethink and reapply the same level of rigor on 
tumours as that on in vitro cultures. In order to better understand the behaviors 
of the cancerous cells after the nanomedicine treatment, we performed explant 
cultures of the tumour pre-treated with our micelle formulations, and 
attempted to re-examine in greater detail whether our drug-micelle system is 
indeed efficacious through ex vivo investigation. 
In this chapter, the tumour was excised from the animal model after treatment 
(chapter 5) and cultured for cellular studies. We also explant cultured the  
tumour cells and further analysed the cellular response to in vivo micelle 
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treatment, with special attention to outcomes of angiogenesis, migration, cell  
cycle and apoptosis. It is noteworthy that, during the explant culture, the cells 
were not further exposed to any drugs, in order to maintain the nature of the 
tumour cells as close as they had been in the tumour mass within the animal. 
6.2 Materials and methods 
6.2.1 Materials 
Tali® apoptosis kit (A10788), Alexa Fluor® 488 mouse anti-human IgG1, 
ProLong Gold antifade reagent with DAPI solution, fetal bovine serum (FBS) 
and penicillin-streptomycin solution were provided by Invitrogen. Dulbecco’s 
Modified Eagle’s Medium (DMEM) and rabbit polyclonal antibody to Ki-67 
(RM-9106) were purchased from Thermo Scientific (USA). All solvents used 
in this study were HPLC grade. Rabbit anti-CD31 polyclonal antibody 
(AB28364) and biotinylated goat anti rabbit antibody (AB64256) were 
purchased from Abcam (USA). RNeasy fibrous tissue mini kit was obtained 
from Qiagen (USA).  iScript
TM
 cDNA synthesis kit and SsoAdvanced 
Universal SBYR Green qPCR Supermix were purchased from Biorad (USA). 
D-Luciferin and O.C.T. tissue freezing medium were purchased from 
PerkinElmer (USA) and Leica Microsystem (USA), respectively. TNBC 
MDA-MB-231/Luc cells were purchased from Cell Biolabs (USA).  
6.2.2 Tumour explant cell culture 
A sample of tissue was dissected from each tumour and maintained at  4°C in 
DMEM medium supplemented with 10 % FBS and 1 % penicillin-
streptomycin solution before processing for culture according to a reported 
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protocol (Pei et al. 2004). The tumour specimens were washed in DMEM 
medium and then cut into small pieces and plated into 6-well plates.  The 
culture plates were incubated at 37°C in the presence of 5 % CO2. Any tumour 
fragments not placed in culture were frozen at –80°C to preserve the tissue for 
subsequent analysis.  
6.2.3 Tumour apoptotic assay 
The excised tumour was incubated in the cell culture medium. After 
incubation for 24 h, the MDA-MB-231/Luc cells were collected from the 
explant cell cultures (Control, Dox, TP, TPD, and TPDC micelles treated 
groups). The cells were stained with the Tali® apoptosis kit as recommended 
by the manufacturer. The percentage of apoptotic cells was determined with 
Tali® Image-Based Cytometer (Life Technologies, Singapore). 
6.2.4 Ex vivo scratch assay 
MDA-MB-231/Luc cells were collected from the explant cell cultures 
(Control, Dox, TP, TPD, and TPDC micelles treated groups). The explant cells 
were seeded on 96-well transparent plates (Costar, USA) at 5×10
3 
cells/well 
(0.1 mL) until confluence was attained.  This was followed by the creation of a 
scratch with a sterile clear pipette tip. The cells were then washed twice with 
PBS to remove debris and detached cells. The cells were incubated in the 
DMEM media at 37°C and monitored at the start of the experiment and after 
12 h using a phase-contrast inverted microscope (Olympus, Japan). The 
acquired images were analysed using software (ImageJ) to determine the 
migration index of tumour cells into the scratched area by measuring and 









          (1) 
where w0 and w12 denote the scratch width at the start of the experiment and 
12 h after scratch was created. A migration index value of 1 indicates full 
closure of the scratched region.  
6.2.5  Cell migration using Transwell insert 
Transwell insert migration assays were conducted on MDA-MB-231/Luc cells 
collected from the explant cell cultures (Control, Dox, TP, TPD, and TPDC 
micelles treated group). The cells were resuspended in serum-free DMEM and 
5 × 10
4 
cells were added onto 8-µm transwell inserts (Greiner, USA). The 
lower chamber was filled with 1 mL of DMEM with 10 % FBS.  After 12 h of 
incubation at 37°C and 5 % CO2, the transwell insert was removed from the 
plate. Then, cotton-tipped was used to remove the media and remaining cells 
that had not migrated from the top of the membrane without damaging the 
membrane. Migrated cells on the underside of the filter were fixed in 70 % 
ethanol for 20 min prior to staining with DAPI. Membranes were mounted on 
glass slides and cells were counted using inverted microscope Olympus-CX41 
(Olympus, Japan). The sections were then blind-scored by 6 unbiased 
evaluators of randomly selected sections per group. 
6.2.6 Immunofluorescence and immunohistochemistry of tissue sample 
Tissue samples were fixed with 4 % PFA for 24 h. The fixed tissue samples 
were rinsed with 1×PBS thrice and dried with paper towel before embedded 
with the O.C.T. tissue freezing medium. The tissue samples then were flash 
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frozen in the liquid nitrogen and were stored in –80°C prior to the sectioning. 
Sections of 10 μm were cut with a Cryostat (LeicaMicrosystems, USA).  
For immunofluorescence detection of CD31, tissue sections were 
permeabilized using 0.2 % Triton X-100 in 1×PBS for 15 min and blocked 
with blocking solution (2 % BSA, 0.1 % Triton X-100 in 1×PBS ) for 1 h. The 
sections were incubated overnight at 4°C with rabbit polyclonal antibody to 
CD31 (1:200) in 1×PBS with 0.2 % BSA. The tissue sections were washed 
with 1×PBS twice after incubation. The washed sections were incubated with 
Alexa Fluor
®
 488 chicken anti-rabbit antibody (1:400) for 1 h. The labelled 
tissue sections were washed with 1×PBS twice before mounted with ProLong 
Gold antifade reagent with DAPI. 
For immunohistochemistry detection of Ki-67 proliferating marker, tissue 
samples were fixed by immersing the slides with pre-chilled acetone for 10 
min. After removing the fixative, the sections were dried at room temperature 
for 20 min to allow acetone to evaporate. The dried slides were rinsed with 
1×PBS twice. The sections were incubated with 0.3 % H2O2 in 1×PBS 
solution to block endogenous peroxidase activity. The tissue sections were 
rinsed with 1×PBS twice. The sections were blocked with blocking buffer (10 
% FBS and 1 % BSA in 1×PBS) at room temperature for 1 h. After removal of 
the blocking buffer, rabbit polyclonal antibody to Ki-67 (1:200) in 1×PBS 
with 0.5 % BSA was added on the sections for 30 min incubation. After 
primary antibodies incubation, the sections were washed with 1×PBS twice 
before incubated with biotinylated goat anti rabbit antibody in dark for 30 min. 
The sections were washed with 1×PBS twice. Freshly prepared DAB solution 
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was added onto the sections to reveal the colour of antibody staining. The 
tissue sections were washed with 1×PBS and counterstained with Mayer’s 
Hematoxylin solution. 
6.2.7 Gene expression  
Briefly, total RNA was extracted from the tumour samples (30 mg) using 
RNeasy fibrous tissue mini kit according to the recommended protocol. The 
quantity and quality of the RNA were ascertained with Epoch microplate 
reader (Biotek Instrument, USA). Thereafter, the extracted RNA was reverse 
transcribed to cDNA using iScript
TM
 cDNA synthesis kit following the 
supplier instruction. The gene expression level was then quantified with RT-
PCR method using SsoAdvanced Universal SBYR Green qPCR Supermix on 
CFX96 system (Biorad, USA).  The GAPDH gene was used to normalize the 
gene expression level. The primers used to measure the gene expression level 




Table 6.1 List of primers used in RT-PCR study. 
Gene 
(protein encoded) 
Forward sequence Reverse Sequence 
CMYC (c-myc) 5’–TGGTCGCCCTGCTATGTTG–3’ 5’–CCGGGTCGCAGATGAAACTC–3’ 
TP53 (p53) 5’–TGCTGTCCCCGGACGACGATATT–3’ 5’–GTAGCTGCCCTGGTAGGTT–3’ 
TP73 (p73) 5’–GACGAGGACACGTACTACCTT–3’ 5’–CTGCCGATAGGAGTCCACCA–3’ 
CDK2 (cdk2) 5’–CCAGGAGTTACTTCTATGCCTGA–3’ 5’–TTCATCCAGGGGAGGTACAAC–3’ 
CCNA2 (cyclin A) 5’–GGATGGTAGTTTTGAGTCACCAC–3’ 5’–CACGAGGATAGCTCTCATACTGT–3’ 
CCNB1 (cyclin B1) 5’–AATAAGGCGAAGATCAACATGGC–3’ 5’–TTTGTTACCAATGTCCCCAAGAG–3’ 
IGF1  (IGF-1) 5’–TCTCTTCTACCTGGCGCTGT–3’ 5’–AAGCAGCACTCATCCACGAT–3’ 
VEGF (VEGF) 5’–GGCAGAAGGAGGAGGGACAGAATC–3’ 5’–CATTTACACGTCTGCGGATCTTGT–3’ 
IL1B (IL-1β) 5’–TTCGACACATGGGATAACGAGG–3’ 5’–TTTTTGCTGTGAGTCCCGGAG–3’ 
EGFR (EGFR) 5’–CCCACTCATGCTCTACAACCC–3’ 5’–TCGCACTTCTTACACTTGCGG–3’ 
TGFA (TGFα) 5’–CCTTGGAGAACAGCACGTC–3’ 5’–CCTCCTGCACCAAAAACCT–3’ 
TGFB1 (TGFβ1) 5’–CTAATGGTGGAAACCCACAACG–3’ 5’–TATCGCCAGGAATTGTTGCTG–3’ 
GAPDH (GAPDH) 5’–TGACTCCGACCTTCACCTTC–3’ 5’–TTCGCTCTCTGCTCCTCCT–3’ 
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6.2.8 Statistical analysis.  
Statistical analysis was performed by Student’s t-test for two groups, and one-
way ANOVA for multiple groups. All results were expressed as the mean ± 
standard deviation (SD) unless otherwise noted. A value of p < 0.05 was 
considered statistically significant.  
6.3 Results and discussion 
 
 
Figure 6.1 Schematic cartoon showing the experimental setup for in vivo 






6.3.1 Cell cycle and proliferation effect of the micelles formulations on 
MDA-MB-231/Luc tumour-bearing mice 
Since docetaxel is a tubulin-binding chemotherapeutic agent that inhibits the 
formation of mature mitotic spindles during cell division (Morse et al. 2005), 
we further examined the effects of docetaxel-loaded micellar formulations 
(TPD and TPDC) and free docetaxel on the progression of cell cycle. The up-
regulation and down-regulation of cell cycle genes including G2/mitotic-
specific cyclin-B1 (CCNB1), cyclin-A2 (CCNA2), and cyclin-dependent 
kinase 2 (CDK2) were quantified with PCR (qPCR). Figure 6.2 shows 
significant down-regulation for TPD, TPDC and docetaxel compared with the 
control, suggesting that docetaxel induces cell cycle arrest as expected. 
Among the groups, the TPDC formulations induced a greater extent of cell 
cycle genes downregulation, which potentially reflects a higher therapeutic 
effect due to effective delivery of the drugs into the tumour cells, compared 
with free drug formulation. Furthermore, vitamin E TPGS micelles alone (TP) 
did not induce significant cell cycle arrest, the expression of cell cycle genes 







Figure 6.2 Vitamin E TPGS micelles formulated docetaxel drug (TPD and 
TPDC) induced cell cycle arrest. qPCR analysis of tumours for cell cycle 
indicate that Dox, TPD and TPDC significantly induced cell cycle arrest. 
Expression level was normalized against control.  Data are means ± SD, n = 3. 
Student’s t-test compared to control, *p < 0.05. Dox = Taxotere®; TP = 
vitamin E TPGS micelle without drug; TPD = docetaxel-loaded vitamin E 





The proliferation effect was examined on the tumour tissues by 
immunohistochemistry staining with the proliferating marker, Ki-67. The Ki-
67 was detected less significantly on the TPD and TPDC treated groups, 
suggesting a lesser degree of tumour proliferation when compared to the 
control group (Figure 6.3). These ex vivo investigations of the excised 
tumours also corroborated with our in vivo progressive observations of 
significantly impaired tumour growth in the TPD and TPDC groups (See 
section 2.3.3). This further reinforces the finding that the efficacy of vitamin E 
TPGS micelles enables them to be a powerful docetaxel carrier and delivery 
system for stunting tumour growth at the cellular level. Interestingly, no 
significant changes in the level of apoptosis were observed for tumours treated 
with docetaxel (Figure A1 and Figure A2). This may be due to the 
mechanism of action of docetaxel through induction of cell cycle arrest and 












Figure 6.3 . Vitamin E TPGS micelles formulated docetaxel drug (TPD 
and TPDC) inhibited Ki-67 expression in MDA-MB-231 cells. TPD- and 
TPDC-treated cells exhibited attenuated cell proliferation (reduction of Ki-67 
staining) in MDA-MB-231 breast cancer tissues. Scale bar = 200 µm. Dox = 
Taxotere
®
; TP = vitamin E TPGS micelle without drug; TPD = docetaxel-
loaded vitamin E TPGS micelles; TPDC = cetuximab-conjugated docetaxel-
loaded vitamin E TPGS micelles. 
 
6.3.2 Anti-angiogenesis induced by micelles on MDA-MB-231/Luc 
tumour-bearing mice 
Tumours require an ample supply of oxygen and nutrients from blood vessels 
in order to support their high proliferation rate.  Tumours stimulate 
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angiogenesis and, as they progress, begin to exploit the proximal blood vessel 
network to metastasize. Therefore, we were interested in investigating whether 
our micelles possessed anti-angiogenesis and anti-migration properties, 
considering that enhanced docetaxel delivery to the nearby angiogenic 
endothelial cells and to the tumour cells might reduce angiogenesis and 
metastasis respectively.  
We investigated the anti-angiogenic effect of TPD and TPDC micelles on the 
tumour tissues with immunofluorescence staining of CD31, a blood vessel 
marker. Figure 6.4 shows that the CD31 staining was notably lower in tumour 
tissues treated with TPD and TPDC compared with the untreated control. 
Intense staining of CD31 was observed for the tumour treated with only 
docetaxel and with vitamin E TPGS micelles. We next quantified the 
angiogenesis gene expression of vascular endothelial growth factor (VEGF), 
interleukin-1β (IL1β) and insulin-like growth factor 1 (IGF-1) using qPCR 
(Figure 6.5). We observed that  tumours treated with TPDC micelles 
exhibited significant down-regulation for VEGF, IL1β and IGF-1 by 
approximately 0.38-, 0.73-, and 0.53-fold, respectively, compared with the 
control. However, non-targeting micelles also exhibited down-regulation for 
VEGF. Collectively, these  findings showed that there was significant 
reduction of blood vessels for  tumours treated with targeting and non-
targeting micelles, in alignment  with the trend observed in the CD31, blood 
vessel marker staining. Furthermore, vitamin E TPGS micelles treatment of 
the tumour did not exhibit down-regulation of any of these genes. This 
indicates that the effect of anti-angiogenesis is due to the enhanced delivery of 
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Figure 6.4 Targeting micelles suppress CD31 expression in MDA-MB-231 
tumours. Examination of intra-tumoural blood vessels through 
immunofluorescence staining with anti-CD31 antibody of tumour tissues 
revealed that TPDC micelles suppressed CD31 expression. Green fluorescence 
from Alexa Fluor® 488 indicates the expression of CD31 whereas blue 
fluorescence from DAPI indicates stained nuclei. Scale bar = 30 µm. Dox = 
Taxotere
®
; TP = vitamin E TPGS micelle without drug; TPD = docetaxel-
loaded vitamin E TPGS micelles; TPDC = cetuximab-conjugated docetaxel-






Figure 6.5 Targeting micelles induce anti-angiogenic effect in MDA-MB-
231 tumours. qPCR analysis of tumours for angiogenesis showed that TPDC-
treated tumours down-regulated VEGF, IL1B and IGF1 genes. Expression 
level was normalized against control. Data are means ± SD, n = 3. Student’s t-
test compared to control, *p < 0.05. Dox = Taxotere
®
; TP = vitamin E TPGS 
micelle without drug; TPD = docetaxel-loaded vitamin E TPGS micelles; 





6.3.3 Anti-migration effects induced by micelles on MDA-MB-231/Luc 
tumour-bearing mice 
We next investigated whether TPD and TPDC micelles would inhibit the 
migration of tumours. Figure 6.6 and Figure 6.7 depict significant inhibition 
of cell migration for the tumour treated with targeting (TPDC) and with non-
targeting micelles (TPD) with migration indices reduced by 0.098- and 0.28-
fold, respectively, relative to the control. In contrast, no significant inhibition 
of cell migration was observed for tumours treated with docetaxel and with 





Figure 6.6 TPDC slows down MDA-MB-231 cells migration. Scratch assay 
indicates that TPD- and TPDC-treated ex vivo explanted tumour cells (MDA-
MB-231/luc) have a significantly lower rate of cell migration than other 
groups. Scale bar = 200 µm. Dox = Taxotere
®
; TP = vitamin E TPGS micelle 
without drug; TPD = docetaxel-loaded vitamin E TPGS micelles; TPDC = 




Figure 6.7 Migration index of TPDC-treated tumours shows significant 
inhibition of cell migration. Data are means ± SD, n = 3. Student’s t-test 
compared to control,*p < 0.05. Dox = Taxotere
®
; TP = vitamin E TPGS 
micelle without drug; TPD = docetaxel-loaded vitamin E TPGS micelles; 
TPDC = cetuximab-conjugated docetaxel-loaded vitamin E TPGS micelles. 
 
We next performed transwell migration assays to further confirm the 
migration properties of the ex vivo explanted tumour cells. The transwell 
stained section scoring yielded a similar trend, i.e. the TPD- and TPDC-treated 





Figure 6.8 Transwell insert migration study confirms that TPD and 
TPDC slow down tumour migration. Assessments were made by six 
unbiased evaluators of randomly selected sections per group. Data are means ± 
SD, n = 6. Student’s t-test compared to control,*p < 0.05.  Dox = Taxotere®; 
TP = vitamin E TPGS micelle without drug; TPD = docetaxel-loaded vitamin 
E TPGS micelles; TPDC = cetuximab-conjugated docetaxel-loaded vitamin E 
TPGS micelles. 
 
The expression of certain genes critical to metastasis including epidermal 
growth factor receptor (EGFR),  transforming growth factor-alpha (TGFA) 
and transforming growth factor beta 1 (TGFB1)  was quantified with PCR 
(qPCR). The analysis shows significant down-regulation of the migration 
genes for both TPD- and TPDC-treated groups compared with the control 
(Figure 6.9). The reduction in migration of the cancerous cells treated with the 
micellar formulations could be attributed to two important factors: the lack of 
blood vessels which prevents metastases and the effective delivery of 
docetaxel into the cancerous cells, with resultant mitotic arrest via microtubule 







Figure 6.9 qPCR analysis of tumour shows that TPDC-treated MDA-MB-
231 tumours down-regulate the expression of migration genes. Expression 
level was normalized against control. Data are means ± SD, n = 3. Student’s t-
test compared to control,*p < 0.05.  Dox = Taxotere
®
; TP = vitamin E TPGS 
micelle without drug; TPD = docetaxel-loaded vitamin E TPGS micelles; 





In summary, the ex vivo study has demonstrated that tumours treated with 
targeting micelles exhibit enhanced cell cycle arrest and attenuated 
proliferation compared with the control and with those treated non-targeting  
micelles. Furthermore, the ex vivo investigation revealed that both the 
targeting and non-targeting micellar formulations culminated in anti-
angiogenesis effects and inhibition of metastases. Overall, we showed the 
importance of actually checking the tumour cells after treatment and showed 
informative results that could have otherwise been missed if the animal study 
section is just end of the entire study while actually it should be envisioned to 












Chapter 7 Conclusion and Future Perspectives 
This chapter summarizes the major findings with regards to the effects of 
TPDC micelles and EGFR-overexpressed TNBC cells. The major conclusion 
of this work are itemized under the four components of (1) in vitro proof of 
concepts of TPDC micelles efficacious against TNBC cells, (2) the targeting 
effects of TPDC in co-culture condition, (3) the in vivo proof of concepts of 
TPDC micelles efficacious against TNBC cells and (4) the ex vivo study of the 
post treated tumour with micelles formulations. Finally, the recommendations 
for future studies are given.  
7.1 Conclusions 
We have developed a drug delivery system of cetuximab-conjugated, 
docetaxel-loaded vitamin E TPGS micelles (TPDC) for sustainable, controlled 
and targeted delivery of docetaxel into the triple negative breast cancer cells. 
The surface density of the ligands on the micelles was manipulated by using 
various antibody feeding concentrations and their uptake efficiency was 
evaluated on the EGFR-overexpressing MDA-MB-468 cell line. The 
formulation with a definite amount of conjugated ligands with the optimal 
uptake efficacy was selected to represent TPDC for further evaluation. The 
cytotoxicity studies illustrated TNBC resistance to docetaxel and the difficulty 
of inducing cell death in TNBC cells in comparison with ER-/PR- or HER2-
positive breast cancers. This challenge can be overcomed by nanomedicine. 
Besides that, the combination of docetaxel and the targeting ligand further 
enhances the therapeutic effect on all the cell lines, particularly EGFR-
overexpressing cells (MDA-MB-468 and MDA-MB-231).    
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Although excellent uptake of the targeted micelles by EGFR-overexpressing 
cells has been demonstrated the in vitro study using single cell culture, we 
further validated the sensitivity of the TPDC formulation towards EGFR-
overexpressing cells under co-culture condition. The cellular uptake study 
showed that the targeted micelles enhanced the internalisation of the micelles 
into the MDA-MB-231 cells compared with MCF-7. In addition, a greater 
killing effect was observed in the cytotoxicity studies for EGFR-
overexpressing cells upon treatment with TPDC, compared with their non-
EGFR-overexpressing counterparts. The studies further confirm that 
cetuximab on the surface of the micelles exhibits a strong affinity towards 
EGFRs, thereby facilitating the uptake of micelles into the cytoplasm of 
EGFR-expressing cells via receptor-mediated endocytosis.  
The in vivo study was conducted to further validate the efficacy of the TPDC 
on EGFR-overexpressing cells (MDA-MB-231). Fluorescence imaging 
depicts the accumulation of targeted micelles in tumours immediately after 
intravenous injection due to their EPR effect and the cetuximab-facilitated 
uptake of micelles via receptor-mediated endocytosis. This resulted in 
enhanced therapeutic efficacy compared with the free docetaxel and with non-
targeting micellar formulations. The administration of free vitamin E TPGS 
micelles caused no toxicity to the tumours, attesting to the biocompatibility of 
this nanocarrier.  
We further performed ex vivo studies of the tumours in order to elucidate the 
behaviour of the post-treatment cancerous cells.  These results demonstrate 
that tumours treated with targeting micelles exhibit enhanced cell cycle arrest 
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and attenuated proliferation relative to the control and to tumours treated with 
non-targeting micelles.  Furthermore, the ex vivo investigations reveal that 
both the targeting and non-targeting micelles formulations culminated in anti-
angiogenesis and inhibition of metastases. 
7.2 Future Perspectives 
The proof of concept of both in vitro and in vivo results shown above 
evidently suggests that the targeted micellar formulations of docetaxel induced 
greater extents of cellular uptake and killing effects on the EGFR-
overexpressing TNBC cells. However, in this study, we have focused on only 
single-modality treatments i.e. chemotherapy. Since none of single-modality 
treatments can cure cancer effectively, it is proven that multimodality 
treatment improve the therapeutic effects in cancer cells. It is believed that co-
delivery of various therapeutic agents by nanocarriers can further enhance 
killing effects. For example, the combinations of immunotherapy and gene 
therapy using nanomedicine will augment the synergistic effects on triple 
negative TNBC. Although most of the micelles formulations were found to 
accumulate at the tumour but any appreciable distribution of the micelles to 
other sites could lead to the potential off-targeting toxicity. Therefore it is 
important to further improve the targeting specificity of the existing 
formulations such as introducing multiple targeting moieties in a single 
nanocarrier. In addition, it is also important to study the fate of polymeric 
micelles after intravenous administration in vivo to understand the 
pharmacokinetics of the micellar formulation.  Therefore, studies in these 
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Figure A1 TPGS micelles formulated docetaxel does not induce 
apoptosis on explanted MDA-MB-231/Luc tumours. Apoptosis assay to 
examine the effects of different forrmulations on explant cancer cells. Data 
are means ± SD, n = 3. Student’s t-test compared to control, no significant 
difference. Dox = Taxotere®; TP = vitamin E TPGS micelle without drug; 
TPD = docetaxel-loaded vitamin E TPGS micelles; TPDC = cetuximab-







Figure A2 Gene expression analysis of tumours for apoptosis shows 
that the level of CMYC, TP53 and TP73 gene were unchanged for the 
TPDC-treated tumours group. Data are means ± SD, n = 3. Student’s t-
test compared to control, no significant difference. Dox = Taxotere®; TP = 
vitamin E TPGS micelle without drug; TPD = docetaxel-loaded vitamin E 
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